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Summary 
 
 
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder that is 
characterized by the presence of the constitutively active BCR-ABL fusion tyrosine 
kinase. In general, CML is a well-studied disease, but the underlying changes in 
signal transduction networks and gene expression patterns that lead to oncogenic 
reprogramming of haematopoietic cells by the expression of BCR-ABL are only 
incompletely understood. In the present study we are focusing on two different 
aspects of BCR-ABL signalling. One aim was to assess the consequences of BCR-
ABL SH3 domain phosphorylation for the interaction pattern of the fusion protein. In a 
second approach, we sought to identify microRNAs whose expression profile is 
dictated by the tyrosine kinase activity of BCR-ABL. 
 
The SH3 domain of BCR-ABL was previously found to be phosphorylated on Tyr134 
in CML. We conducted biochemical analyses to investigate if Tyr134 phosphorylation 
of the BCR-ABL SH3 domain causes the recruitment of phospho-tyrosyl specific, 
SH2 domain harboring, proteins. We started with a peptide pull-down using two 
synthetic peptides whose sequence corresponded to the region of interest of the 
BCR-ABL SH3 domain. One peptide was modified by the covalent attachment of a 
phosphate group to the tyrosine, while in the other peptide the tyrosine was 
substituted by a phenylalanine. LS-ESI-MS/MS analysis of the pull-downs yielded 
two proteins, PLCG1 and SHP2, which both specifically bind to the tyrosine-
phosphorylated peptide but not to the control peptide. Both candidates have proto-
oncogenic attributes and have already been described to be involved in the 
manifestation of various malignancies. We subsequently coned the BCR-ABL SH3 
domain as a GST fusion protein into a bacterial expression vector, and after 
expression in E. coli and FPLC-purification we performed additional pull-downs, this 
time comparing the fully folded SH3 domain with a control construct where the 
tyrosine residue of interest was mutated to phenylalanine. Finally, overexpression of 
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various full-length BCR-ABL constructs in HEK-null cells was performed to confirm 
the phosphotyrosine dependent interaction between the BCR-ABL SH3 domain and 
the potential interactors in co-immunoprecipitation experiments. To our knowledge 
this is the first study showing a phosphotyrosine dependent interaction between an 
SH2 domain and an SH3 domain. Considering the pro-growth nature of PLCG1 and 
SHP2 it is entirely thinkable that Tyr134 phosphorylation represents a further 
mechanism by which BCR-ABL exerts its oncogenic function. 
 
MicroRNAs (miRNAs) are a novel class of small noncoding RNAs that modulate the 
expression of genes at the posttranscriptional level. Aberrant miRNA expression has 
been described in several human malignancies, including CML. 
In the second part of this study we provide an informative profile of the expression of 
miRNAs that are deregulated upon Dasatinib or Nilotinib treatment of K562 cells. We 
identified 31 miRNAs that were differentially expressed in the presence of tyrosine 
kinase activity suppressed BCR-ABL. In line with previous findings, expression of 
miRNAs belonging to the miR-17-92 family was specifically downregulated by both 
Dasatinib and Nilotinib treatment. In addition we detected a marked decrease of miR-
21 in the drug treated samples, confirming earlier microarray gene expression data. 
Furthermore, we observed miR-21 downregulation also by a miR-21 specific miR-
qRT-PCR assay. Finally, we used the TargetScan platform for the identification of 
predicted miRNA target genes whose expression levels inversely correlate with any 
of the 31 miRNA candidates following BCR-ABL inhibition in K562 cells. In summary, 
the results of this study offer a comprehensive and quantitative profile of BCR-ABL 
dependent miRNA expression in CML and further implicate the oncogenic miRNAs 
miR-17-92 and miR-21 in the pathophysiology of the disease. 
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Zusammenfassung 
 
 
Bei der Chronischen Myeolischen Leukämie (CML) handelt es sich um eine 
umfassend charakterisierte myeloproliferative Erkrankung, die aus der anhaltenden 
Aktivität der Tyrosinkinase BCR-ABL resultiert. Trotz der Vielzahl an bereits 
gewonnen Erkenntnissen sind weiter Untersuchungen notwendig um die der 
Krankheit zugrunde liegenden Veränderungen in Signaltransduktion und 
Genexpression gänzlich zu verstehen. In der vorliegenden Studie wurden zwei 
Aspekte der BCR-ABL abhängigen Signaltransduktion genauer untersucht. Einen 
Schwerpunkt legten wir auf die Charakterisierung jener Änderungen im 
Interaktionsprofil von BCR-ABL, die durch die Phosphorylierung der BCR-ABL 
eigenen SH3 Domäne verursacht werden. Im zweiten Projekt suchten wir nach 
mikroRNAs, deren Expressionsprofil von der Aktivität der BCR-ABL Tyrosinkinase 
bestimmt wird. 
 
Bereits in einer früheren Studie wurde gezeigt, dass bei CML die SH3 Domäne von 
BCR-ABL am Tyr134 phosphoryliert wird. Wir führten verschiedene biochemische 
Analysen durch, mit dem Ziel Proteine zu identifizieren die über eine etwaige SH2 
Domäne mit BCR-ABL über eben diesen phosphorylierten Tyrosinrest interagieren. 
Wir behalfen uns dabei eines sogenannten Peptid Pull-downs. Kurze synthetische 
Peptide wurde designt deren Sequenz dem Tyr134 umgebenden Bereich der SH3 
Domäne entspricht. Eines der beiden Peptide wurde durch das kovalente Anhängen 
einer Phosphatgruppe and Tyr134 modifiziert. Im zweiten Peptid, dem Kontrollpeptid, 
wurde das Tyrosin durch einen Phenylalaninrest ersetzt. Die 
massenspektrometrische Analyse beider Pull-downs führte zur Identifizierung von 
PLCG1 und SHP2, zwei Proteine die spezifisch das Tyrosin-phosphorylierte Peptid 
binden, jedoch nicht an das Kontrollpeptid. Beiden Kanditaten wurden bereits in 
frühern Studien eine Rolle in der Entwicklung verschiedener Tumorarten 
zugeschrieben. In einem nächsten Schritt klonierten wir die SH3 Domäne BCR-ABLs 
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als GST-Fusionsprotein in einen bakteriellen Expressionsvektor. Nach der 
Aufreinigung der in E. coli exprimierten SH3 Domäne mittels FPLC führten wir weiter 
Pull-down Experimente durch. Diesmal verglichen wir die vollständige SH3 Domäne 
mit einem Kontrolkonstrukt bei dem wiederum Tyr134 durch ein Phenylalanin 
subsituiert wurde. Die abschließende Verifizierung erfolgte über einen Co-
Immunoprezipitationsansatz, bei welchem wir verschiedene BCR-ABL Konstrukte 
hinsichtlich einer spezifischen Interaktion zwischen PLCG1 und SHP2 und der 
Tyrosin phosphorylierten SH3 Domäne untersuchten. Es dürfte sich hierbei um die 
erste Studie halten, die eine Phosphotyrosin abhäbgige Interaktion zwischen eine 
SH2 Domäne und einer SH3 Domäne zeigt. In Anbetracht der 
wachstumsbegünstigenden Natur von sowohl PLCG1 als auch SHP2 ist es nicht 
auszuschließen, dass die Phosphorylierung von Tyr134 einen weiteren 
Mechanismus der BCR-ABL vermittelten Onkogenese darstellt. 
 
MikroRNAs (miRNAs) sind neuartige, kurze nicht kodierende, RNAs, die die 
Expression von Genen auf posttranskriptioneller Ebene modulieren. Die aberrante 
Expression von miRNAs wurde in Verbindung zu zahlreichen bösartigen zellulären 
Veränderungen, einschließlich CML gebracht. 
Im zweiten Teil unserer Studie wurden 31 miRNAs identifiziert deren 
Expressionprofile durch die Inkubation von K562 Zellen mit Dasatinib  und Nilotinib 
signifikant verändert wurden. Wir konnten in Übereinstimmung mit früheren Studien 
zeigen, dass die Expression von miRNAs der miR-17-92 Familie durch Inhibierung 
der BCR-ABL Aktivität negativ reguliert wird. Ferner beobachteten wir eine Reduktion 
der miR-21 Expression durch sowohl Dasatinib als auch Niltoinib, und verifizierten 
dadurch das Ergebnis einer schon länger zurückliegenden Mikroarray basierenden 
Genexpressionsanalyse. Eine weitere Bestätigung der Runterregulierung von miR-21 
wurde durch eine  miR-21 spezifische miR-qRT-PCR Analyse erzielt. Anhand der 
TargetScan Plattform bestimmten wir abschließend die Zielgene der idenfizierten 
miRNAs und konzentrierten uns dabei auf jene Gene deren Expressionslevel 
umgekehrt proportional zu den Expressionsleveln der jeweiligen miRNAs verlaufen. 
In der vorliegenden Studie wird eine umfassende Analyse der BCR-ABL abhängigen 
miRNA Expression durchgeführt. Außerdem liefern wir weitere Hinweise dafür, dass 
die onkogene miRNAs miR-17-92 und miR-21 an der Pathophysiologie von CML 
beteiligt sind. 
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1. Introduction 
 
 
1.1. Chronic Myeloid Leukemia 
 
Chronic myeloid leukemia (CML) is a clonal disorder caused by the neoplastic 
transformation of hematopoietic stem cells (HSCs). A common distinctive feature of 
all CML patients is the presence of a consistent chromosomal abnormality – the  
Philadelphia (Ph) chromosome – a reciprocal translocation involving the long arms of 
chromosomes 9 and 22, t(9;22) (q34;q11). This translocation leads to the 
juxtaposition of the 3´ end of the Abelson kinase proto-oncogene (ABL1) on 
chromosome 9 with the 5´end of breakpoint cluster region (BCR) on chromosome 22 
forming a BCR-ABL fusion gene 1-3. The new gene encodes the oncoprotein 
p210BCR/ABL, a constitutively active tyrosine kinase which promotes cell survival and 
proliferation through several intracellular signal transduction pathways 4, 5. In a series 
of studies it was shown that expression of BCR-ABL in mouse bone-marrow cells 
using retroviral transduction and bone-marrow transplantation methods is sufficient 
for the induction of a myeloproliferative disorder that has all the major hallmarks of 
CML proving the direct causal relationship to CML 6-8. 
CML is characterized by distinct clinical phases and evolves through a multi-step 
pathogenetic process (Fig. 1.1). In the initial, chronic phase of the disease (CP) 
expression of the BCR-ABL fusion gene in self-renewing HSCs causes a massive 
expansion of the mature, granulocytic cell lineage 9, 10. After 3-4 years, the disease 
progresses into the accelerated phase (AP) which typically lasts 4-6 months and is 
characterized by an increase in the amount of progenitor cells. Finally patients enter 
the blast phase (BP) in which hematopoietic differentiation has become arrested and 
a rapid expansion of lymphoid and myeloid progenitor cells (blast cells) in bone 
marrow, peripheral blood and extramedullary tissues occurs 11, 12. 
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The exact mechanism responsible for the transition from CML chronic phase to blast 
phase is only incompletely understood. It seems however reasonable to assume that 
the unrestrained BCR-ABL activity is essential for the acquisition of additional 
cytogenetic and molecular defects that result in the manifestation of symptoms with 
increasingly malignant characteristics. For example it has been shown that BCR-ABL 
expression causes genomic instability by interfering with DNA repair pathways and 
thereby triggers chromosomal aberrations 13-16 The most frequent oncogenic events 
associated with blast crisis include loss of p53 function 17, 18, trisomy 8, i(17q) 19, 20, 
MYC amplification 19, RB (RB1) deletion/rearrangement 21, p16INK4A (CDKN2) 
rearrangement/deletion 22, and reduplication of the Ph chromosome 20.  
In addition, the increased levels of BCR-ABL in the advanced stages of the disease 
are likely to contribute to reduced apoptosis susceptibility, enhanced proliferation 
potential and differentiation arrest of the leukemic clone 5. 
Figure 1.1 Development of CML. Hematopoietic stem cell (HSC), myeloid progenitor (MP), 
lymphoid progenitor (LP), granulocytic/macrophage progenitor (GMP), megakaryocyte/erythrocyte 
progenitor (MEG), macrophage (M). (Taken from Ref.4) 
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1.2. BCR-ABL: regulation & signalling 
 
C-Abl, the endogenous counterpart to BCR-ABL, is a ubiquitously expressed non-
receptor tyrosine kinase which has been implicated in various cellular processes 
including proliferation, differentiation, apoptosis, stress response, cell migration and 
cell adhesion 23, 24.  
Alternative splicing of the primary ABL transcript generates two messenger RNAs 
encoding different isoforms of the c-ABL protein. Isoform 1b is 19 amino acids longer 
than the 1a splice variant and is myristoylated on its second glycine residue, a site 
absent in isoform 1a and BCR-ABL 25 (Fig. 1.2).  
 
 
 
 
 
 
 
The kinase activity of c-ABL is tightly regulated and in its basal state is kept inactive 
by intramolecular interactions. The autoinhibited state of c-ABL is initiated by the 
intramolecular engagement of the N-terminal myristoyl modification of the 5‟ Cap 
region with a hydrophobic pocket of the kinase domain 26. This event induces a 
conformational change that allows the formation of the so called „SH3-SH2 clamp‟.  
Within this „clamp‟ structure the Src homology domain 3 (SH3) and the Src homology 
domain 2 (SH2) of c-ABL bind to the distal side of the tyrosine kinase domain thereby 
causing a conformational change at the base of the activation loop and hence 
rendering the enzyme inactive 25, 27. The activation loop is a highly flexible stretch of 
amino acids that is projecting into the active site of the kinase domain and 
participating in the coordinated binding of ATP and peptide substrate 25.  
Figure 1.2 Domain structures of the ABL family. (Taken from Ref.25)  
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Although c-ABL isoform 1a is not myristoylated it appears to be regulated through an 
indistinguishable mechanism. It was suggested that hydrophobic residues in the Cap 
domain of c-ABL 1a may substitute for the myristoyl latching function 26, 27. 
The full activation of c-ABL is thought to require a three step mechanism (Fig. 1.3). 
First of all, “unlatching” of the myristoyl group or hydrophobic residues in the kinase 
domain has to occur. Secondly, engagement of the SH2 and SH3 domains with 
tyrosyl phosphorylated peptides and proline rich proteins, respectively, is likely to 
open up the clamp structure. Phosphorylation of tyrosine 245 in the linker between 
SH2 and kinase domain is contributing to the disassembly due to the now impaired 
SH3-linker interaction of the autoinhibited structure. As a result the activation loop is 
reoriented and exposed outwards, leading in a third step to the phosphorylation of 
tyrosine 412 and to full kinase activation 26-31. 
.  
 
 
 
 
 
1.3. Mechanisms of BCR-ABL mediated malignant 
transformation 
 
In order for BCR-ABL to exert its oncogenic function it relies on several features that 
were shown to be critical for cellular transformation and disease progression 4, 32-35. 
 
Figure 1.3 Mechanism of c-ABL activation. (Taken from Ref.28) 
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1.3.1. Deregulated kinase activity 
 
Obviously, deregulation of the otherwise tightly regulated kinase activity is one of 
them. Fusion of BCR sequences to ABL results in the partial deletion of the c-ABL 
Cap region that contains the myristoylation site and is absolutely required for c-ABL 
regulation 36. BCR-ABL as a consequence is able to evade the autoinhibitory 
mechanism observed in c-ABL, explaining its constitutive kinase activity and the 
increase in autophosphorylation and cellular total phosphotyrosine levels. Because of 
its catalytic activity, many substrates can be tyrosine phosphorylated by BCR-ABL. 
Even more important, autophosphorylation leads to a marked increase of 
phosphotyrosine on BCR-ABL itself, which creates docking sites for SH2 or PTB 
domain harboring proteins. 
 
 
1.3.2. Oligomerization 
 
Oligomerization is a further feature that is contributing to BCR-ABL induced cellular 
transformation. The amino-terminal coiled-coil domain (CC) mediates dimerization 
and tetramerization of the BCR-ABL protein 37 and enhances its kinase activity 38. It 
was shown in mice that lack of the BCR-ABL CC domain results in the inability of 
BCR-ABL to induce a myeloproliferative disorder (MPD), emphasizing its importance 
in the process of neoplastic transformation 39-41.  
 
 
1.3.3. Aberrant signalling 
 
Finally, BCR-ABL regulates a diverse range of signalling molecules and pathways 
whose contribution in leukemogenesis is based on the following features 32, 34, 35: 
 
Mitogenic signalling| Of all the signalling pathways with mitogenic potential in BCR-
ABL–transformed cells, activation of the RAS MAP kinase system appears to play a 
central role in myeloid proliferation and survival. It was shown that impairment of 
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RAS signalling severely suppresses BCR-ABL induced cell growth 42-44 and that 
expression of an oncogenic form of RAS in mice induces an MPD 45, 46.  
Absolutely required for the induction of an MPD is the GRB2-binding site in the Bcr-
region of BCR-ABL 39, 41, 47. If phosphorylated, tyrosine 177 binds the SH2 domain of 
GRB2, which in turn recruits SOS and GAB2 48, 49. SOS is a guanine-nucleotide 
exchange factor of RAS and is therefore turning on the RAS MAP kinase pathway. 
GAB2 on the other hand is a scaffolding protein that recruits PI3K and SHP2 – the 
latter acting upstream of RAS and being required for full activation of the Erk MAP 
kinase pathway 50, 51.  
Beside Y177 there exist two additional sites that are contributing to the activation of 
RAS 52: The SH2 domain of BCR-ABL was shown to recruit SHC, which, following 
tyrosine-phosphorylation, can, recruit GRB2 52. For the second site – tyrosine 1294 – 
again a tyrosine-phosphorylation site, located in the activation loop of the kinase 
domain, the mechanism of RAS activation is still unsolved. It was however shown 
that mutation of the SH2 domain as well as of Y1294 attenuates leukemogenesis by 
BCR-ABL 53-55.  
 
Cell survival| BCR-ABL promotes cell survival partly by activating the PI3K pathway 
56 whose dysregulation has been implicated in contributing to the onset of a wide 
range of human cancers 57. The next relevant downstream substrate of PI3K in this 
cascade is the serine-threonine kinase AKT. AKT negatively regulates apoptosis by a 
multifactorial mechanism that is involving the phosphorylation of several components 
of the cell-death machinery (BAD, Caspase-9, FKHR, MDM2 and IKK) 57 
Inhibition of the PI3K pathway by expression of dominant negative AKT or application 
of a PI3K inhibitor compromises BCR-ABL–induced cytokine-independent growth 58 
and colony formation 59. There exist however also contradictory reports that show 
that expression of dominant negative AKT is not sufficient to reverse BCR-ABL 
induced cellular transformation 60, 61.  
It is therefore likely that BCR-ABL relies on additional pathways to ensure 
undisturbed cell survival, like activation of STAT5 54, 62, inhibition of the p38 MAPK, or 
downregulation of JunB 63, 64 and ICSBP 65 transcription. 
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Loss of stromal cell adhesion| In the bone marrow microenvironment, regulation of 
hematopoiesis normally involves adhesion of hematopoietic progenitor cells to 
marrow stoma cells and extracellular matrix components. This interaction negatively 
regulates cell proliferation and prevents premature circulation of primitive progenitors 
in the blood. In CML, however, malignant progenitor cells appear to escape this 
regulation by virtue of their altered adhesion properties 66, 67.  Aberrant β1 integrin 
signalling has been implicated in this process. Treatments with IFNα or an activating 
anti-β1-integrin antibody have been shown to reverse the adhesion and proliferation-
inhibitory signalling defects observed in CML 67-69. 
 
Proteasomal degradation of c-ABL inhibitors| Yet another, quite compelling, 
mechanism by which BCR-ABL is guaranteeing the progress of leukemogenesis is 
proteasome-mediated degradation of proteins with otherwise inhibitory function 32. 
Mutational analysis of the c-ABL SH3 domain led to the discovery of point mutants 
with enhanced catalytic and transforming activities. These mutations were at 
residues predicted to obstruct binding of PxxP ligands 70. The Abl interacting proteins 
ABI-1 and ABI-2 contain such motifs. Binding of ABI-1 and ABI-2 to the SH3 domain 
of c-ABL negatively regulates its tyrosine kinase activity and antagonizes its 
oncogenic function 71-73. BCR-ABL seems to overcome this obstacle by inducing 
ubiquitination and proteasome-mediated degradation of ABI-1 and ABI-2 73.  
Significantly, degradation of the ABI proteins is specific for Ph-positive leukemias and 
is not seen in BCR-ABL-negative samples of comparable phenotype. 
 
Inhibition of tumour suppressors| Although still speculative, recent work suggests 
that loss of tumour suppression function is a further mechanism by which BCR-ABL 
is contributing to malignant propagation and progression. There is mounting data 
corroborating the theory that BCR-ABL is fostering oncogenesis through interaction 
and subsequent downregulation of tumour suppressors.  
The cyclin-dependent kinase (CDK) inhibitors (CDKI) p16ink4a and p19Arf, for example, 
bind to CDK and are consequently promoting cell senescence by stalling the cycle 35. 
BMI1 is polycomb gene which represses p16ink4a and p19Arf mediated senescence to 
promote cell survival and self-renewal by epigenetic gene silencing 74, 75. 
Phosphorylated p38 MAPK has been implicated in causing the dissociation of BMI1 
from chromatin via its downstream effector 3pK 35, 76.  
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In normal cells c-ABL has stimulatory effects on p38 and the CDKIs and is hence 
directing the cell towards senescence. In CML cells, BCR-ABL is inhibiting the 
normal tumour suppressor activity of p38, which, following de-phosphorylation loses 
its inhibitory effect on BMI1. As a result p16ink4a and p19Arf expression is repressed 
and a shift away from senescence toward unrestrained cell proliferation and survival 
occurs 35, 77, 78. 
The protein phosphatase 2A (PP2A) is another tumour suppressor that is inhibited by 
BCR-ABL 34, 79. In the chronic phase of the disease, PP2A antagonizes BCR-ABL 
through recruitment and activation of the tyrosine phosphatase SHP1.  SHP1 
catalyses the dephosphorylation of BCR-ABL, which in turn is downregulated through 
proteasomal degradation 79. While the activity of PP2A is only moderately impaired in 
the chronic phase of CML, its activity in blast phase cells is negligible. It was found 
that in CML blast crisis (CML-BC) progenitors, the phosphatase activity of PP2A is 
inhibited by the BCR-ABL-induced post-transcriptional upregulation of the PP2A 
inhibitor SET – a phosphoprotein that is frequently overexpressed in leukemias and 
solid tumours 79. 
 
Differentiation arrest| In CML progression a transition from mature, terminally 
differentiated cells to immature, undifferentiated cells can be observed. The 
differentiation arrest can be explained by the pathological interference of BCR-ABL 
with the corresponding differentiation programmes. It has been demonstrated that 
BCR-ABL suppresses the translation of the transcription factor CEBP and is thereby 
preventing the expression of the granulocyte colony-stimulating factor receptor 
(GCSFR) and ID1 genes 80-82. The effect of BCR-ABL on CEBP is mediated by the 
translational regulator HNRNPE2. BCR-ABL increases the stability of HNRNPE2, 
which, following binding to the CEBP mRNA, inhibits the translation of the 
transcription factor 82. 
 
Genomic instability| The transition from CML chronic phase to blast crisis is 
associated with increased genomic instability. The reasons for this are reduced 
capacity of CML cells to survey the genome for DNA damage, interference with DNA-
repair proteins and progressive telomere shortening (reviewed in 34). 
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Many more signalling molecules are regulated by BCR-ABL, but for the majority of 
them it is still rather unclear if and to what extent they are contributing to the onset of 
BCR-ABL induced leukemia.  
In addition to the aforementioned proteins, the list of BCR-ABL interactors includes  
for example CRKL, CRK-II, STS-1, SHIP-2, CBL, p85, 3BP2, CAS, STAT5, PLCg, 
FAK, RASA, paxilin, talin, synaptophysin,  etc. 4. Also, signalling downstream of 
BCR-ABL is known to activate various transcription factors (e.g. MYC, STAT5, NF-
kb) and to induce the expression of different cytokines (e.g. IL-3, GM-CSF) 4. 
 
 
1.4. BCR-ABL as a therapeutic target 
 
Historically, first chemotherapy using hydroxyurea, cytosine arabinoside, arsenic 
trioxide and later INF-α was used to treat CML patients 83. Chemotherapy was 
insufficient in delaying disease progression and was hence associated with a rather 
poor prognosis 84, 85. Treatment with IFNα, often in combination with the DNA 
synthesis inhibitor cytarabine (Ara-C), represented a significant advance, producing 
hematologic and cytogenetic responses in patients with CP CML, and improving the 
survival rate compared with previous treatments 86, 87.  
A major breakthrough in CML treatment has arrived with the development of small 
molecule chemical inhibitors that allow molecular targeted therapies against specific 
oncogenic events. The discovery that BCR-ABL is required for the pathogenesis of 
CML, and that the tyrosine kinase activity of c-ABL is imperative for the transforming 
properties of BCR-ABL, made the BCR-ABL kinase domain an attractive target for 
therapeutic intervention 88. 
 
 
1.4.1. Imatinib 
 
The first tyrosine kinase inhibitor (TKI) directed against BCR-ABL to be developed 
was Imatinib (also known as Gleevec, STI571, or CP57148B). Imatinib is a potent 
inhibitor of ABL, ARG, KIT, and PDGFR tyrosine kinases and has been shown to be 
remarkably successful in treating patients with CML as well as other blood 
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neoplasias and solid tumors based on the deregulation of these tyrosine kinases‟ 
activity 33, 89. Imatinib binds to the cleft between the N- and C-terminal lobes of the 
kinase domain outside of the highly conserved ATP binding site thereby obstructing 
ATP binding. In doing so, Imatinib effectively inhibits the catalytic activity of ABL, 
trapping the activation loop of the kinase domain in an inactive conformation 90-92.  
Imatinib selectively induces apoptosis of BCR–ABL positive cells and induces 
hematologic and cytogenetic remissions in all phases of CML, although treatment of 
patients with more advanced phases of CML is less effective and less durable than it 
is in the early phase of the disease 93-97.  
However, there are two major obstacles to Imatinib based therapies for patients with 
CML. One is the persistence of quiescent leukemic stem cells, which Imatinib fails to 
deplete despite the presence of higher levels of BCR-ABL transcripts and protein in 
these cells compared with more differentiated CML cells 98-100.  The insensitivity of 
these cells to Imatinib is believed to contribute to the relapse observed in some 
patients following the termination of Imatinib treatment, which is why the only way to 
suppress the disease is continuous Imatinib therapy. 
The other major problem is Imatinib resistance. A significant proportion of patients is 
intrinsically resistant to Imatinib or develops resistance during treatment 101. Several 
studies also suggest that a very small subpopulation of leukemic cells exists that 
harbors mutant subclones prior to Imatinib treatment and which grows in prevalence 
during therapy owing to the selective pressure of the drug 102, 103. 
Imatinib resistance is often a result of single point mutations that impair drug binding 
in the tyrosine kinase domain and allow BCR-ABL to circumvent an otherwise potent 
anticancer drug 101, 104, 105. Usually this involves the re-emergence of BCR-ABL 
tyrosine kinase activity, indicating that the mutant BCR-ABL protein is still a putative 
target for inhibition in Imatinib-resistant patients 106-108. Other mechanisms that 
contribute to Imatinib resistance include increased expression of BCR-ABL kinase 
through gene amplification, decreased intracellular Imatinib concentrations caused by 
increased expression of drug efflux proteins or decreased expression of drug influx 
proteins and Imatinib binding by plasma proteins 85. 
The discovery of resistance mechanisms spurred the development of alternative 
therapies designed to overcome Imatinib resistance, including high-dose Imatinib, 
novel targeted agents, and combination treatments 83, 109, 110. 
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1.4.2. Dasatinib 
 
Dasatinib (Sprycel, Bristol-Myers Squibb) has recently been approved for treatment 
of patients with CML following failure or with intolerance to Imatinib therapy.  It is a 
highly potent multitargeted TKI that inhibits several critical oncogenic proteins, 
including BCR-ABL, Src family of kinases (SFKs), Kit, PDGFR, and ephrin A 
(EPHA2) receptor kinase 111-113.  
Dasatinib binds BCR-ABL with greater affinity than Imatinib and unlike Imatinib it 
binds primarily the active conformation of the enzyme 111, 114, 115. As a result, 
Dasatinib has been shown to effectively inhibit all Imatinib-resistant kinase domain 
mutations tested, with the exception of the T315I mutation 114, 116, 117.  
A potential limitation of Dasatinib is the occurrence of untoward off-target toxicities, 
which probably relate to its inhibitory activity against a broader range of protein 
kinases than Imatinib 109. 
 
 
1.4.3. Nilotinib 
 
Nilotinib (Tasigna, Novartis) is a derivative of Imatinib, and similar to Imatinib it binds 
BCR-ABL in its inactive conformation only 83. Nilotinib is however even more 
selective, having only similar activity to Imatinib against KIT and PDGFR, and being 
devoid of activity against the related SFKs 110. Moreover, Nilotinib is about 30-fold 
more potent in inhibiting BCR-ABL than Imatinib and has demonstrated activity 
against 32 of 33 mutant BCR-ABL forms resistant to Imatinib, again with the 
exception of T315I 118, 119 
 
 
1.4.4. Other inhibitors 
 
Several other BCR-ABL inhibitors are currently in clinical trials including dual Src 
family and ABL kinase inhibitors (Bosutinib, INNO-404 and AZD0530), non-ATP 
competitive inhibitors of BCR-ABL (ON012380) and Aurora kinase inhibitors (MK-
0457 and PHA-739358) 110. MK-0457 and ON012380 may even be capable of 
inhibiting the T315I mutant of BCR-ABL 120-122. 
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1.5. SH2 & SH3 domains 
 
The Src homology domains SH2 and SH3 are conserved protein domains that act as 
key regulatory participants in many different signalling pathways. Independent of 
surrounding sequences, both domains fold into functional and compact modules that 
recognize short peptide motifs containing either phosphotyrosine (pTyr) in the case of 
SH2, or proline-rich regions in the case of SH3. 
Both domains belong to a group of conserved building blocks that are mediating 
protein-protein interactions and that are common to a variety of signalling proteins. 
Thus, they are assuming an important role in regulating many distinct cellular 
processes that are based on the coordinated interaction of proteins within complex 
signalling networks. 
 
 
1.5.1. The SH3 domain 
 
The SH3 domain has a characteristic fold which consists of five or six beta-strands 
arranged as two tightly packed anti-parallel beta sheets, resulting in a β-barrel-like 
structure 123. The surface of the SH3 domain bears a relatively flat, hydrophobic 
ligand-binding surface, which is composed of two ligand-binding pockets (sites 1 and 
2) defined by highly conserved aromatic residues (Trp, Tyr or Phe), and a third, more 
variable specificity pocket (site 3) 124-127.  
The core of the proline-rich peptide ligand consists of approximately 10 amino acids 
and contains the consensus X-P-x-X-P, where X tends to be an aliphatic residue and 
the two prolines (P) are crucial for high affinity binding 127-129. Peptides associating 
with the SH3 domain adopt an extended, left-handed polyproline type II (PPII) helix 
conformation, with three residues per turn. This results in a roughly triangular shape 
in cross-section, where each of the X-P dipeptides at the base of the triangle is 
occupying one of the two hydrophobic ligand-binding pockets of the SH3 domain. 
The third groove of the SH3 domain makes specific contacts with a residue in the 
ligand distal to the X-P-x-X-P core. Although interactions at this position are more 
variable, they tend to involve an acidic residue in the SH3 domain and an Arginine, or 
less often Lysine, in the ligand 123, 126, 130-133. 
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Due to the symmetry of the PPII helix conformation, the presence of the basic 
“specificity” residue at an amino-terminal (R/K-x-X-P-x-X-P) or carboxy-terminal (X-P-
x-X-P-x-R/K) position in the peptide gives rise to two possible interaction modes. 
Depending on the peptide orientation one distinguishes between class I (amino- to 
carboxy-terminal orientation, i.e. the Arginine fitting into site-3 pocket lies at the 
carboxy-terminal end of the peptide) and class II (carboxy- to amino-terminal 
orientation, i.e. the Arginine lies at the amino-terminal end) ligands 130, 131, 133, 134. 
The Abl SH3 domain is atypical in that it prefers class I ligands in which hydrophobic 
residues such as methionine or tryptophan contact the specificity pocket. This is 
because it lacks the conserved acidic residues of other SH3 domains that usually 
dictate the selection of arginine at this site in the target sequence 123, 128, 132, 135. 
Generally, the target specificity of particular SH3 domains has been addressed in a 
host of studies using phage display libraries and combinatorial peptide libraries. 
Apparently each SH3 domain has a distinct binding preference, the specificity being 
conferred by the interactions between the non-proline residues in the ligand and the 
site-3 specificity pocket formed by residues from the RT and n-Src loops, two 
variable SH3 loops flanking the main hydrophobic binding surface 124, 127, 132, 136-141.  
Nevertheless, compared to hydrogen-bonding interactions, hydrophobic interactions 
are generally less specific. As a consequence SH3-peptide binding affinities are quite 
weak, with KD values typically ranging from 1 µM to approximately 10 µM 
142. Often, 
SH3 domains achieve biological specificity only by exploiting multiple binding sites 
and tertiary interactions between the parent protein and its target 142. 
 
1.5.2. The SH2 domain 
 
The SH2 domain is a compact structure containing approximately 100 amino acids 
and recognizing phosphorylated tyrosine residues in specific sequence contexts 127, 
143-148. Its structure is composed of an amino-terminal α-helix (αA) and a central anti-
parallel β-sheet (strands βA-βD), followed by a smaller β-sheet (βD´, βE, βF), a 
second α-helix (αB) and a carboxy-terminal β-strand (βG) 142, 149-154 (Fig. 1.4). The 
central β-sheet divides the SH2 domain into two functionally distinct sides, yielding a 
bipartite structure. One side, flanked by helix αA, is a conserved pTyr binding pocket 
which is separated from a second, more variable ligand binding surface, that typically 
engages residues C-terminal to the pTyr. This second side is flanked by helix αB, the 
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smaller β-sheet and the loops between helix αB and strand βG, and between the β-
strands E and F (called BG and EF loops, respectively). 
The bound phospho-peptide usually lies perpendicular to the central β-sheet of the 
bound SH2 domain in an extended conformation 154. Therefore, the interaction 
between the SH2 domain and the peptide is largely independent of the context of the 
native protein from which the peptide is taken.  
The interaction of the phosphotyrosine group with the conserved pocket of the SH2 
domain is the major driving force of the SH2-ligand binding process 142. Two Arginine 
residues, one from helix αA and one from strand βB (conserved in all SH2 domains) 
make key contacts with the pTyr by forming hydrogen bonds with the two phosphate 
oxygens 127, 154.  Phosphotyrosine binding alone, however, provides only about half 
the free energy of binding 153. Efficient phospho-peptide binding therefore relies 
additionally on a series of weak interactions between the amino acids immediately C-
terminal to the pTyr (P+1 – P+5) and the corresponding residues in the specificity 
pocket of the SH2 domain. These residues are determining the sequence specificity 
of the SH2 domain and are located in the EF and BG loops as wells as at position 
βD5 (nomenclature according to the structure of the Src SH2 domain) 142, 154.  βD5 is 
a residue that shows contacts with both the P+1 and P+3 residues of the phospho-
peptide  in many SH2-ligand complexes 155. 
Huang et al. recently described the use of an oriented peptide array library (OPAL) to 
determine the phosphotyrosyl peptide-binding properties of the human SH2 domains 
156. In the same publication it was proposed to categorize the human SH2 domains 
into three major groups, according to their βD5 identity. Group I SH2 domains contain 
an aromatic residue such as Tyr or Phe at this position and prefer a general 
consensus poYξξΦ, where ξ and denote Φ a hydrophilic and a hydrophobic residue 
respectively. Group II SH2 domains contain a hydrophobic, but non-aromatic residue 
such as Ile, Leu, Val, Cys, or Met at βD5. The last major group of SH2 domain, group 
III, is composed solely of the STAT family of transcription regulators and has a 
hydrophilic βD5 such as Glu, Gln or Lys. 
In summary, the SH2-peptide interaction is of moderate strength with a dissociation 
constant ranging between 0.1 µM and 1 µM, the affinity to phospho-peptides of 
random sequence being ~1,000 lower 127, 142, 157-159.  
 
 1. INTRODUCTION  
15 
 
 
 
 
 
1.6. MicroRNAs 
 
MicroRNAs (miRNAs) are a family of single-stranded non-coding RNAs of 21–25-
nucleotides that negatively regulate gene expression at the post-transcriptional level 
in a sequence-specific manner 160-168. Bioinformatic predictions indicate that the 
human genome encodes approximately 800-1000 miRNAs which are estimate to 
regulate roughly ~30% of all protein-coding genes 162, 169. 
Functional studies have implicated miRNAs as key players in the regulation of a host 
of cellular pathways and there is increasing evidence, suggesting that miRNA 
deregulation underlies several human pathologies, including cancer 165, 166, 170-173. 
 
 
Figure 1.4 The structure of SH2 domains. (Taken from Ref.154) 
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1.6.1. Biogenesis and mechanism 
 
With some exceptions, miRNA transcription is usually mediated by RNA polymerase 
II (Pol II) 174-176. MiRNA genes are either located in intergenic regions and are 
transcribed as autonomous transcription units, or they are portions of introns of 
protein-coding open reading frames (ORFs) 177-179.  Furthermore, many miRNAs are 
encoded in close proximity to other miRNAs and are transcribed from a single 
polycistronic transcription unit, ensuring their coordinated expression (e.g. in 
development) 177, 178, 180, 181. 
The primary miRNA transcripts (pri-miRNAs) have stemloop like shapes, contain 
5´cap structures, are polyadenylated, and can range in size from a few hundred 
nucleotides to several hundred kilo bases 175, 176, 182.   
Within the nucleus pri-miRNA processing is initiated by a complex consisting of the 
RNase III type endonuclease Drosha, and its partner DGCR8 183-186. The Drosha-
DGCR8 complex catalyses pri-miRNA cleavage, leading to the excision of a ~70nt 
hairpin precursor RNA (pre-miRNA) with a 2-nucleotide overhang at the 3´ end. This 
overhang is characteristic of RNase III mediated cleavage and serves as structural 
requirement for recognition by the nuclear export factor exportin5, which transports 
the pre-miRNA into the cytoplasm 187-190. There, the pre-miRNAs are cleaved by 
another RNase III enzyme, Dicer, which interacts with the dsRBD protein TRBP, to 
yield ~21-bp miRNA:miRNA*(star) duplexes with protruding 2-nucleotide 3´overhangs 
191-195. Only one strand is then selected to function as a mature RNA (referred to as 
the guide strand), while the other strand, known as the passenger strand, or miRNA*, 
is typically degraded. The strand with thermodynamically less stable base pairing at 
its 5´end (i.e., more A:U base pairs or mismatches) is usually destined to become the 
mature miRNA and is chosen for incorporation into a ribonucleoprotein complex 
(RNP) known as RNA-induced silencing complex (RISC) 192, 196, 197. The so formed 
complexes are henceforth called miRNPs or miRISCs and their main component 
beside the miRNA guide strand is the Argonaute family protein AGO2 167, 198-201.  
The assembled miRISC complex accomplishes gene silencing through two major 
mechanisms, depending on the degree of complementarity between a miRNA and its 
target mRNA 202-204. In plants most miRNAs exhibit nearly perfect complementarity to 
their target mRNAs and are therefore triggering RISC mediated endonucleolytic 
mRNA cleavage (slicing) by an RNAi like mechanism 205-207. Silencing is achieved 
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through an Argonaute protein, possessing endonucleolytic activity. Mammals contain 
four Argonaute proteins (AGO1-AGO4), but only AGO2 has an RNaseH-like PIWI 
domain, which cleaves mRNA at the centre of the siRNA-mRNA duplex 208-211. Most 
animal miRNAs however, usually base pair imperfectly with corresponding binding 
sites in the 3´UTR of target mRNAs, thereby promoting translational repression 
rather than active degradation of the mRNA 165-168, 212 (Fig. 1.5). 
 
 
 
 
 
 
The precise mechanism that underlies post-transcriptional gene repression by 
miRNAs is still a subject of discussion.  There is evidence suggesting that 
translational repression occurs at the initiation step, whereas other studies suggest 
that miRNAs interfere with translational elongation or termination. Possible 
mechanisms of miRNA-mediated gene repression include the induction of mRNA 
deadenylation and decay, the blocked initiation of translation at either the cap-
recognition stage or the 60S subunit joining stage, the repression at post-initiations 
steps owing to either slowed elongation or ribosome “drop-off”, and the proteolytic 
Figure 1.5 Possible mechanism of microRNA mediated post-transcriptional gene 
silencing. (Taken from Ref.167) 
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cleavage of nascent polypeptides (extensively reviewed in 167). Following 
translational repression, the affected mRNAs are probably moved to so-called P-
bodies for either degradation or temporary storage 167. P-bodies are discrete 
granules that are localized in the cytoplasm of eukaryotic cells and that were 
demonstrated to be enriched in mRNA-catabolizing enzymes, AGO proteins, 
miRNAs, miRNA repressed mRNAs and translational repressors 213-222.  
 
 
 
1.6.2. MiRNA target prediction 
 
In order to elucidate the function of a certain miRNA it is inevitable to identify them 
target genes whose expression it regulates. However, the identification of potential 
miRNA targets in metazoans is quite challenging, because, as mentioned before, 
miRNAs are usually imperfectly complementary to their targets. 
The interaction between a given miRNA and its target mRNA follows a set of rules 
determined by experimental and bioinformatic analyses 223-227. In animals, the most 
consistent feature of miRNA-target interaction is base pairing at the 5´ end of the 
miRNA. In particular, perfect and contiguous base pairing of the miRNA „seed‟ 
region, which comprises nucleotides 2-8, is considered to be most important, 
although not always necessary. Another criterion is the presence of bulges or 
mismatches in the central region of the miRNA-mRNA duplex, precluding the AGO-
mediated endonucleolytic cleavage of mRNA. A third rule is that there must be 
reasonable complementarity between mRNA and the miRNA 3‟ half to stabilize the 
interaction or to compensate for suboptimal matching in the seed region. Finally, 
effective post-transcriptional repression requires the presence of multiple binding 
sites for the same or different miRNAs in the mRNA 3´UTR.  
Based on these principles, a diverse array of bioinformatic approaches have been 
applied to develop web-based tools that predict miRNA-target sites. The different 
algorithms utilize at least some of the following criteria to identify and prioritize 
putative targets: (a) complementarity between the miRNA seed sequence and the 
3´UTR of the target mRNA; (b) the overall stability of putative miRNA-target 
duplexes; (c) miRNA target site conservation between closely related species; (d ) 
multiple binding sites for a single miRNA within a given target 3´UTR; and (e) weak 
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or no secondary structure in the target at the miRNA-binding site 166. The advantages 
and caveats of the different prediction tools are discussed in 228. 
 
 
1.7. MiRNAs in cancer (leukemia) 
 
MiRNAs are involved in the regulation of cancer-relevant processes such as 
proliferation, apoptosis and tissue differentiation 162, 229, establishing an important role 
for miRNAs in the pathogenesis of cancer. The examination of miRNA expression 
profiles in tumor-specific tissues has revealed a widespread dysregulation of miRNA 
molecules in a broad range of cancers 230, 231. Intriguingly, significantly differing 
miRNA profiles can be assigned to various types of tumors, illustrating the potential 
for miRNAs to act as novel diagnostic and perhaps prognostic markers 230, 232. 
The differential expression of miRNA genes in malignant compared to normal cells 
can at least to some extent be attributed to the location of these genes in cancer-
associated genomic regions, to epigenetic mechanisms, and to alterations in the 
miRNA processing machinery 232.  
It has recently been shown that more than 50% of miRNA genes reside in particular 
genomic regions that are prone to alterations in cancer cells and are often harboring 
tumour-suppressor genes or proto-oncogenes 233. Typical locations include minimal 
regions of amplification, minimal regions of loss of heterozygosity (LOH), common 
breakpoint regions as well as fragile sites (preferential sites of sisterchromatid 
exchange, translocation, deletion, amplification or integration) 233. 
Furthermore, the protein machinery that is involved in the biogenesis of miRNAs is 
quite complex and theoretically, alterations of its components should have dramatic 
effects on miRNA expression. In fact, altered expression levels of Dicer, Drosha and 
Argonaute proteins have already been associated with various types of cancer 170. 
The third mechanism implicated in the regulation of miRNA expression involves 
modifications on the DNA and histone level, interfering with miRNA transcription 232, 
234. Epigenetic markers like DNA hypomethylation, CpG island   hypermethylation or 
aberrant histone-modification are a very common feature of malignant transformation 
and it is conceivable that such events also affect miRNA expression. Recent 
publications seem to support this notion 233, 235, 236. 
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Although, for most miRNAs it is still unknown whether they actually play an active 
role in tumorigenesis, there exist a few miRNAs that have been causatively linked to 
cancer formation. 
 
 
1.7.1. MiRNAs as tumor suppressors 
 
MiR-15 & 16| The initial evidence for the involvement of miRNAs in cancer came 
from a report by Calin et al. that showed that the chromosome region 13q14 is 
deleted in most cases of B-cell chronic lymphocytic leukemia (CLL) 237. This locus 
contains two clustered miRNA genes, encoding miR-15a and miR-16-1, and no other 
genes could be identified in this region. Accordingly, the expression levels of these 
miRNAs were shown to be reduced in over two thirds of CLL patients 237, 238. 
In a recent publication Cimmino et al. demonstrated that miR-15a and miR-16-1 
negatively regulate BCL2 expression at a posttranscriptional level 239. BCL2 is an 
anti-apoptotic protein which is frequently overexpressed in CLL and whose 
expression levels in CLL are inversely correlated to those of miR-15a and miR-16-1 
239. This suggests that the deletion of the tumor-suppressor genes mir-15a and mir-
16-1 results in increased expression of BCL2, promoting abnormal survival of CLL 
cells. 
 
Let-7| Humans possess twelve homologs of the C. elegans let-7 miRNA in eight 
distinct clusters, four of which are located in genomic regions known to be deleted in 
cancer 233. Emerging evidence suggests that let-7 is a tumor suppressor that plays a 
critical role in the pathogenesis of lung cancer, reduced let-7 expression being 
associated with a rather poor prognosis 240, 241. Let-7 is negatively regulating the 
expression of MYC and RAS, two key oncogenes in lung cancer that contain multiple 
let-7 binding sites in their 3′ UTR 242. 
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1.7.2. MiRNAs as proto-oncogenes 
 
MiR-203| A miRNA with potential tumor suppressor activity, implicated in specific 
hematopoietic malignancies, is miR-203. The miR-203 gene is located in the 14q32 
region of human chromosome 14, a fragile chromosomal region that is especially rich 
in microRNAs, expressing 52 mature microRNAs 243.  
Expression profiling of T-cell lymphoma cells revealed significant silencing of miR-
203 due to the loss of one allele and promoter CpG hypermethylation in the 
remaining allele 243. Also, this miRNA gene was shown to be additionally 
hypermethylated in CML and B cell acute lymphoblastic leukemia (B-cell ALL) 243, 
plus, the 14q32 region is frequently lost in CML BC patients 244, 245.   
In the same study miR-203 was shown to target ABL and BCR-ABL, whose 
expression levels inversely correlated with the expression level of miR-203 243. 
Reexpression of miR-203 reduced ABL and BCR-ABL protein levels and inhibited 
tumor cell proliferation. This antiproliferative effect was partially rescued by BCR-ABL 
overexpression and fully rescued by a BCR-ABL cDNA without the endogenous 
3´UTR 243. 
It is therefore conceivable that there exists a specific pressure to inactivate miR-203 
in Ph-positive tumors (CML, B-cell ALL) or tumors that overexpress ABL (T-cell 
lymphomas). 
 
MiR-17-92| MiRNAs with oncogenic potential are expressed from the polycistronic 
miR17-92 locus 13q31, which is amplified in lung cancer and several kinds of 
lymphoma, including diffuse large B-cell lymphoma 246-248. Also, widespread 
overexpression of these miRNAs has been observed in diverse types of cancer, 
including CML 231, 249. 
In the human genome, the miR-17-92 cluster encodes six miRNAs (miR-17, miR-
18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1) and both, the sequences of these 
mature miRNAs and their genomic organization, are highly conserved in all 
vertebrates 250. 
Transcription of the miR-17-92 cluster is activated by the oncogenic transcription 
factor MYC, which regulates cell growth, apoptosis and metabolism, and which is 
pathologically activated in a large fraction of human malignancies 251, 252. MYC is also 
directing the transcription of E2F1, a member of the E2F family of transcription 
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factors that control the transition from G1 to S phase of the cell cycle by regulating 
genes that are involved in DNA replication, cell division and apoptosis 253.  
Interestingly, the E2F family transcription factors were among the first verified targets 
of the miR-17-92 miRNAs 251, 254, 255. Also, E2F1 can in turn directly activate the 
transcription of these miRNAs, establishing a negative feedback loop 250. Considering 
that high levels of E2F1 can induce apoptosis, this circuitry allows MYC to 
simultaneously activate E2F1 transcription and limit its translation, thereby promoting 
cell division rather than cell death 170, 246, 250. 
 
MiR-155| Another miRNA with oncogenic potential is miR-155, located in the only 
phylogenetically conserved region of the B cell integration cluster (BIC) 256. 
Overexpression of BIC/miR-155 is linked to MYC overexpression and occurs 
frequently in B cell lymphomas including Burkitt lymphoma, Hodgkin lymphoma and 
diffuse large B cell lymphoma (DLBCL) 256-261. It therefore appears that miR-155 is 
promoting or accelerating lymphomagenesis in cooperation with MYC 170. 
MiR-155 has also been reported to be upregulated in tumors of the breast, lung, 
colon and thyorid, indicating that there are further roles for this miRNA outside of the 
hematopoietic system 231, 262, 263. 
 
MiR-21| Mir-21 is an oncogenic miRNA that has been linked to an array of human 
cancers. Volinia et al. demonstrated that miR-21 is overexpressed in tumors derived 
from breast, colon, lung, pancreas, stomach, and prostate 231. Further support for the 
function of miR-21 in tumorigenesis came from a series of studies implicating miR-21 
overexpression in breast cancer 264-267, colorectal cancer 268, hepatocellular 
carcinomas (HCC) 269, 270, myelomas 271, cholangiocarcinomas 272 and glioblastomas 
273, 274, as well as myeloproliferative disorders like CLL 275, DLBCL 276 and CML (data 
not published). The most prominent miR-21 targets that were identified in the course 
of these studies are known tumor suppressors like PTEN, TPM1, PDCD4 and 
maspin (SERPINB5), underlying the oncogenic potential of miR-21. Accordingly, 
miR-21 was shown to exert an anti-apoptotic function and to promote tumor growth, 
increased metastasis and increased invasion.  
The miR-21 gene is located on chromosome 17 immediately downstream of the 
TMEM49 coding region. The promoter region of miR-21 contains two STAT3 binding 
sites and it was shown by Loffler et al. that miR-21 expression is induced by IL-6 in a 
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STAT3 dependent mechanism 271. STAT3 is a transcription factor whose activation is 
essential for cellular transformation and oncogenesis 277, 278. 
 
Obviously, many more miRNAs were shown to be either upregulated or 
downregulated in cancer, but, as pointed out earlier, for the majority of them a 
causative link to tumorigenesis has yet to be established. 
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2. Aim of studies 
 
 
2.1. Tyrosine-phosphorylation of the BCR-ABL SH3 
domain 
 
BCR-ABL is a very potent oncogene, which, due to its kinase activity and its multiple 
functional sites and domains, acts as a central signalling hub in CML cells. Being 
placed upstream of various signalling pathways it determines the cellular fate, 
guiding it towards neoplastic transformation. In order for this to happen BCR-ABL 
relies on its protein modules that undergo extensive interactions with a broad range 
of molecules, representing the first shell of the oncogenic signalling cascade.  
In this study we are focusing on the BCR-ABL SH3 domain and are seeking to 
elucidate its role in leukemogenesis.  
 
In 2001, in a publication by Li et al., it was shown that GRB2 is tyrosine-
phosphorylated in BCR-ABL expressing cells on Tyr209, a site that is located within 
the GRB2 C-terminal SH3 domain 279. Binding of the GRB2 SH2 domain to BCR-ABL 
phosphotyrosine Y177 was shown to be decisive for GRB2 phosphorylation. The 
same study revealed that binding of the guanine nucleotide exchange factor SOS to 
GRB2 was markedly decreased in vivo and in vitro upon Tyr209 phosphorylation. 
 
Tyr209 of GRB2 is a highly conserved residue among different SH3 domains, and is 
directly involved in binding PxxP ligands 130. Bioinformatic analyses revealed that the 
BCR-ABL SH3 domain contains a tyrosine residue, Tyr134, which is located in the 
exactly same structural position as Tyr209 of the GRB2 C-terminal SH3 domain (Fig. 
2.1).  
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The resemblance between the two SH3 domains led to the question as to whether 
Tyr134 is also getting phosphorylated.  This question was answered by Steen et al. 
who mapped BCR-ABL phospho-tyrosine residues, applying phospho-tyrosine 
specific immonium ion scanning 280. They identified nine different phosphorylated 
tyrosine sites, one of which corresponded to Tyr134 of the SH3 domain. Supporting 
evidence for Tyr134 phosphorylation came from a recent report describing the SFK 
dependent phosphorylation of the BCR-ABL SH3 domain 281. According to their 
results, Tyr134 is predominantly phosphorylated by the SRC family kinase HCK. 
Considering that phosphorylation of the GRB2 C-terminal SH3 domain interferes with 
the GRB2 binding pattern it is tempting to speculate that a similar effect might be 
observed for BCR-ABL. According to our model there exist two plausible scenarios of 
how Tyr134 phosphorylation could affect interactions mediated by the SH3 domain. 
One possibility is that phosphorylation of Tyr134, either through BCR-ABL (trans-
)autophosphorylation or by SFKs, could lead to a „loss-of-function‟ scenario, where, 
similar to the decreased SOS binding observed for the GRB2 C-terminal SH3 
domain, SH3 dependent interactions of BCR-ABL with other proteins may no longer 
Figure 2.1 Structural similarity between BCR-ABL SH3 domain and GRB2 C-
terminal SH3 domain. BCR-ABL SH3 domain (pink), GRB2 SH2 domain and C-
terminal SH3 domain (yellow). 
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be possible or at least be markedly decreased. On the other hand, it is also 
conceivable that phosphorylation of the BCR-ABL SH3 domain results in a „gain-of-
function‟ situation, where phosphorylated Y134 serves as a docking site for a 
different set of interactors. In the latter case, new binding partners would be expected 
to contain an SH2 domain or a different phosphotyrosine recognizing module. 
 
 
 
 
 
 
In a recent publication by Donaldson et al. an interaction between the ABL SH3 
domain and the SH2 domain of the adaptor molecule CRK-II was shown to occur 282. 
Upon tyrosine-phosphorylation of CRK-II by ABL, autorecognition of the newly 
phosphorylated site by the CRK-II SH2 domain induced an intramolecular 
reorganization 282-284. A conformational change in the CRK-II SH2 domain led to the 
Figure 2.2 Project outline. 
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exposure of a proline-rich loop located between the βD and βE strands of the SH2 
domain (DE loop) 282, 285. This extended 20-residue DE loop is unique to the 
mammalian CRK-II SH2 domain and was shown to be recognized by the regulatory 
SH3 domain of ABL, yielding a ternary complex consisting of the ABL SH3 domain, 
the CRK-II SH2 domain and a CRK-II phosphopeptide 282, 285. 
Although the formation of this complex differs in its mechanism from the proposed 
interaction occurring between the phosphorylated BCR-ABL SH3 domain and SH2 
domains of potential interactors, it nevertheless proves that such modular binding 
domains may have modes of recognizing biological partners that are beyond their 
canonical ligand binding.  
 
Based on the observations made by Li et al. and Steen et al. we are predicting that 
phosphorylation of Y134 of the BCR-ABL SH3 domain affects the SH3 binding 
pattern. In particular we were interested in the „gain-of-function‟ scenario, our focus 
being directed to the identification and characterization of novel, SH2 domain 
harboring, interactors of BCR-ABL, which bind in the presence of phosphorylated 
Y134 only. 
 
 
2.2. MiR-21 
 
MicroRNAs (miRNAs) are an abundant class of short nonprotein-coding RNAs 
(ncRNAs) mediating posttranscriptional silencing of target genes. They have been 
shown to play key regulatory roles in a diverse range of pathways, including 
proliferation, apoptosis, differentiation, and cell fate determination 162, 229. As a 
consequence, miRNA deregulation has immediate implications for a many 
physiologic processes. There is emerging evidence that aberrant miRNA expression 
is causatively linked to the pathogenesis of a variety of disorders, including human 
malignancies 230, 231. In this context miRNAs can function as tumor suppressors or 
oncogenes, depending on whether they specifically modulate the expression of tumor 
suppressor genes or oncogenes 170, 173. 
Considering that characteristic miRNA expression profiles can be obtained for 
particular tumor types, miRNAs may serve as biomarkers for diagnostics and to 
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predict clinical outcomes, and may eventually be exploited as therapeutic targets 230, 
232. 
Besides the diagnostic and prognostic significance of miRNAs, defining disease 
specific miRNA signatures will hopefully provide new insights in the pathogenesis of 
diseases in which the etiology is only incompletely understood. 
 
In the present study we are focusing on the identification and eventual 
characterization of miRNAs that are deregulated in the presence of BCR-ABL in 
chronic myeloid leukemia. 
 
It is known that miRNAs play an important role in the regulation of hematopoiesis, 
and there is rapidly accumulating evidence to suggest that dysfunctional expression 
of miRNAs is a common feature in hematological malignancy 286, 287. 
In a recent publication by Venturini et al. aberrant expression of the miR-17-92 
polycistron in CML has been reported 249. BCR-ABL positive cell lines were treated 
with either Imatinib or anti-BCR-ABL shRNA, followed by subsequent microarray 
analysis and miRNA-specific quantitative real-time reverse transcriptase PCR (miR-
qRT-PCR) 249. According to this study, inhibition of BCR-ABL tyrosine kinase activity 
results in decreased expression of the miR-17-92 miRNAs, indicating that miRNAs 
form this cluster are upregulated in CML.  
 
In an earlier study we investigated how Dasatinib treatment affects the gene 
expression pattern of K562 cells, a BCR-ABL positive CML cell line. Microarray-
based gene expression profiling showed that many genes are subject of significant 
deregulation in these cells. According to the microarray data, expression of the 
transmembrane protein TMEM49 is supposedly downregulated by a factor of 3.5 in 
Dasatinib treated cells compared to normal K562 cells. However, sequence analysis 
of the corresponding probe revealed that it actually measured the expression of miR-
21, a microRNA, whose coding sequence is located immediately downstream of 
TMEM49. Therefore, we speculated that miR-21 is upregulated in CML, the 
increased expression being caused by the catalytic activity of BCR-ABL. 
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3. Materials and Methods 
 
 
3.1. Cell biology 
 
 
3.1.1. Cell lines and cell culture 
 
K562 human CML cell line expressing endogenous BCR-ABL, established from a 
CML patient in blast crisis, was obtained from DSMZ (Braunschweig, Germany) and 
cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS) 
(Invitrogen) at 37°C in a 5% CO2 incubator. Cells were kept at subconfluency by 
splitting them every 2-3 days, three times a week. 
 
 
3.1.2. Kinase inhibitors 
  
Dasatinib (Sprycel, BMS-354825) and Nilotinib (Tasigna, AMN107) were synthesized 
by WuXi PharmaTech (Shanghai, China). Kinase inhibitors were prepared as 20 mM 
stock solution in DMSO and diluted in the respective cell culture medium to final 
concentrations of 100 nM for dasatinib and 1 µM for nilotinib for all experiments. 
Subconfluent cells were treated with the drugs for 4 hours for RNA isolation. 
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3.2. Protein biochemistry 
 
 
3.2.1. Cell lysates for protein gels 
 
Lysis buffer was prepared by mixing the following protease inhibitors to 
immunoprecipitation buffer (IPB; 50 mM Tris/HCl, pH 7.5; 150 mM NaCl; 1% (v/v) 
Nonidet-P40; 5 mM EGTA, pH 8.0; 5 mM EDTA, pH 8.0, 50 mM NaF, 1 mM 
Na3VO4, 1 mM PMSF (Sigma), 5 μg/ml TLCK (Roche), 10 μg/ml TPCK (Biomol), 1 
μg/ml leupeptin, 1 μg/ml aprotinin and 10 μg/ml soybean trypsin inhibitor (all Roche)). 
Cells were harvested and washed in 10 ml PBS (Invitrogen). Then the pellet was 
resuspended in 50 µl to 200 μl ice cold lysis buffer, to reach a concentration of 
approximately 1 x 105 cells/μl. The cell pellet was resuspended well to achieve good 
cell lysis and the mixture was immediately centrifuged for 10 min at 13 000 rpm at 
4°C. The supernatant containing the proteins was transferred into a new vial and the 
protein concentration was measured using Bradford assay (Bio-Rad) according to the 
manufacturer‟s instructions using a solution of 1 μg/ml BSA as standard. For 
normalization, the samples were diluted in IP-buffer and the appropriate amount of 4x 
SDS sample buffer (200 mM Tris/HCl, pH 6.8, 40% (v/v) glycerol, 8% (w/v) SDS, 
brom phenol blue, 1.4 M β-mercaptoethanol) was added to reach a protein 
concentration of 100 μg/ 20 μl. The samples were heated at 95°C for 4 minutes and 
directly loaded on the acrylamide gel or stored at -20°C. Cell lysates containing 
100μg total protein were loaded on a discontinuous polyacrylamide gel consisting of 
7% - 15% separating gel (depending on size of protein of interest) and 5% stacking 
gel. As weight marker 5 μl PageRuler Prestained Protein Ladder (Fermentas) was 
used.  
 
3.2.2. Recombinant proteins 
 
To construct GST-SH3 fusion proteins, cDNAs encoding the full-length BCR-ABL 
SH3 domain and the GRB2 C-terminal SH3 domain were inserted into pETM30 in-
frame with GST. GST and GST-SH3 constructs were expressed in E. coli 
BL21(DE3), and extracted using a French Press in Ni-wash buffer (50 mM Tris pH 
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7.5; 500 mM NaCl; 20 mM imidazole; 2 mM ß-mercaptoethanol; 10% (v/v) glycerol). 
Each extract was purified via FPLC using HisTrap HP Columns (1ml, GE 
Healthcare). After washing the column, adsorbed proteins were eluted with a linear 
gradient from 20 mM imidazole to 500mM imidazole (elution buffer: 50 mM Tris 
pH7.5; 500 mM NaCl; 5% (v/v) glycerol; 5 mM β-mercaptoethanol; 500 mM 
imidazole). The resultant proteins were exchanged into storage buffer (20mM 
Tris/HCl pH7.5; 150 mM NaCl; 1 mM DTT) by dialysis. Concentrations of proteins 
were determined using Bradford assay (Bio-Rad) according to the manufacturer‟s 
instructions using a solution of 1 μg/ml BSA as standard.  
 
 
3.2.3. Peptide pull-downs 
 
All peptides used in the pull-down assays were synthesized and quantified by 
Eurogentec (Belgium). Peptide immobilization was performed using the SulfoLink® 
Immobilization Kit for Peptides (Pierce), according to manufacturer‟s instructions. 
Each peptide had a single carboxy-terminal cysteine residue that was used for 
coupling to the SulfoLink coupling resin with a free sulfhydryl group at a 
concentration of 1 mg of peptide per 1ml of gel. In the peptide binding assays, 
coupled peptides were incubated with K562 cell lysates for 4 h and after washing 
three times with 1x PBS (Invitrogen) the protein complexes were eluted by 1% SDS 
and analyzed by LC-ESI-MS/MS and SDS-PAGE. 
 
 
3.2.4. In vitro protein-binding assay (GST pull-down) 
 
Glutathione-Sepharose resin (Amersham Biosciences) was incubated with purified 
recombinant GST or GST-SH3 proteins (each 500µg) in the binding buffer (50 mM 
Tris/HCl, pH 7.5, 100 mM NaCl, 5% (vol/vol) glycerol, 0.2% (vol/vol) Nonidet-P40, 1.5 
mM MgCl2, 25 mM NaF, 1mM Na3VO4 and protease inhibitors) for 1 h. The coupled 
proteins were incubated with K562 cell lysates for 4h and after washing three times 
with the binding buffer the protein complexes were analyzed by LC-ESI-MS/MS and 
SDS-PAGE. 
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3.2.5. Coimmunoprecipitations 
 
HEK-293-null cells (InvivoGen, San Diego, CA) were transfected with pCS2-6xmyc-
BCR-ABL using Lipofectamine (Invitrogen). 48 h later, cells were lysed in 
immunoprecipitation buffer (IPB; 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 
5mM EGTA, 5 mM EDTA, 50 mM NaF, 1mM Na3VO4, 1 mM PMSF, 5 μg/ml TLCK, 
10 μg/ml TPCK, 1 μg/ml leupeptin, 1 μg/ml aprotinin and 10 μg/ml soybean trypsin 
inhibitor). After centrifugation, soluble cell lysates (5mg or 10mg) were 
immunoprecipitated for 5-6 h with anti-MYC antibodies precoupled to agarose 
(Sigma). Beads were washed twice with IPB. Proteins were eluted with SDS sample 
buffer, subjected to SDS/PAGE, and immunoblotted with anti-MYC, anti-c-ABL, anti-
PLCG1 and anti-SHP2 antibodies.  
 
 
3.2.6. In vitro phosphorylation assay 
 
Recombinant His-GST-SH3 fusion proteins were phosphorylated in vitro by 
incubating with the catalytic subunit from Abelson tyrosine kinase (ABL-CD). In vitro 
phosphorylation was performed for 30 min at room temperature in kinase assay 
buffer (20 mMTris/HCl pH7.5, 10 mM MgCl2, 1 mM DTT)  in the presence of 
unlabeled ATP (50 µM) and radioactively labeled [γ-32P]ATP (3000Ci/mmol, 
10mCi/ml). After 30 min TEV protease mediated cleavage of the fusion proteins was 
performed for additional 90 min at room temperature. The reactions were terminated 
by adding 4× SDS sample buffer and boiling for 4 min. The samples were analyzed 
by Tricine-SDS-PAGE on 16% SDS-polyacrylamide gel. The gel was stained with 
Coomassie Blue and dried, followed by autoradiography. To prevent gel cracking 
during the drying process the gel was kept in methanol solution (40% (vol/vol) 
MetOH, 10% (vol/vol) acetic acid, 3% (vol/vol) glycerol) for at least 1 h before using 
the gel-drier. Tricine-SDS-PAGE was performed as described 288.   
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3.2.7. Immunoblotting 
 
After being resolved by SDS-PAGE samples were transferred to a nitrocellulose 
membrane (Whatman Schleicher & Schuell) using a semi-dry blotting apparatus.  
Membrane and gel were sandwiched by 2 layers of Whatman paper and two 
sponges. The transfer was carried out for 1 – 1.5 h at 1 mA/cm2 (transfer buffer: 2.5 
mM Tris, 15 mM Glycine, 10% (v/v) methanol). The quality of the transfer was 
assessed by Ponceau staining. The membrane was blocked in blocking solution for 
20 min at least. Primary antibodies were diluted in blocking solution and incubated 
with the membrane overnight at 4°C.  After washing the membrane three times in 
PBST (0,1% Tween-20 (Sigma) in PBS), the primary antibody was detected using an 
Alexa Fluor 680-labeled goat anti-mouse antibody (Invitrogen) diluted 1:7000 in 
PBST and incubated 1 h at room temperature in the dark. Finally, the blot was again 
washed in 3x in PBST and scanned by the Odyssey Infrared Imaging System (Li-Cor 
Biosciences). BCR-ABL was detected using the mouse monoclonal antibody (clone 
21-63) directed against c-ABL (diluted 1:7000 in 3% (w/v) BSA in PBST). Mouse anti-
PLCG1 (#610028, 1:250 in 5% (w/v) dry milk in PBST) and mouse anti-SHP2 
(#610622, 1:2500 in 5% (w/v) dry milk in PBST) antibodies were obtained from BD 
Transduction Laboratories.  
 
 
3.3. Genomic analysis 
 
 
3.3.1. MicroRNA extraction 
 
For isolating the miRNA, mirVana™ miRNA Isolation Kit from Ambion was used, 
extraction was performed by following the manufacturer‟s protocol. The kit allows the 
isolation of small RNA-containing total RNA through organic extraction followed by 
glass fiber filter mediated purification. 
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3.3.2. Quantitative Real-Time PCR (qRT-PCR) of miR-21 
 
Reverse transcription of miRNAs was performed using the TaqMan™ MicroRNA 
Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's 
recommendations. Briefly, 10 ng of total RNA were combined with dNTPs, 
MultiScribe™ reverse transcriptase, and the miR-21 specific primers. The resulting 
cDNA was diluted 15-fold and used in PCR reactions. PCR was performed according 
to the manufacturer's recommendations (Applied Biosystems). Briefly, cDNA was 
combined with the TaqMan™ assay specific for the miR-21, and PCR reaction was 
done using the Rotor-Gene 6000 (Corbett). Expression of mature miR-21 was 
normalized using the ΔΔCT method relative to RNU43 snoRNA, which was nearly 
equally expressed in untreated and Dasatinib and Nilotinib treated cells. TaqMan 
PCRs for miR-21 and RNU43 were performed in triplicate for each condition (i.e. 
untreated, Dasatinib, Nilotinib). 
 
 
3.3.3. MiR-21 mimics and antagomirs 
 
MiRIDIAN™ mimic, inhibitor, and negative control (Dharmacon) for miR-21, were 
transfected into K562 cells using Hiperfect (Qiagen).  According to the 
manufacturer‟s instructions the molecules were dissolved in ultra pure water to obtain 
a 20 μM stock solution and kept at -20°C. Briefly, 1 × 106 cells were suspended in 
500 µl of RPMI 10% FCS and combined with a mixture of 500 µl RPMI w/o FCS, 18 
µl Hiperfect and 5 μl of the 20 μM miRIDIANTM stock solutions (leading to 100 nM 
miRIDIAN™ solutions). After vortexing and 10 min incubation the cell suspensions 
were transferred into 6-well plates and incubated at 37°C. After 6 h 2 ml of pre-
warmed RPMI 10% FCS were added to the cell suspensions. Transfection was 
repeated after 24 h. Cells were harvested 72 h after the first transfection. 
 
 
3.3.4. MicroRNA profiling 
 
Total RNA was isolated using Trizol reagent (Invitrogen) and further purified using by 
purification over a glass fiber filter column (mirVana; Ambion). Purified RNAs were 
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sent to EXIQON (Denmark) for miRNA expression analysis. MiRNA microarray 
including labeling, hybridization, scanning, normalization and data analysis was 
carried out by EXIQON. Briefly, RNA Quality Control is performed using Bioanalyser 
2100 and Nanodrop. The samples were labeled using the mercury™ Hy3™/Hy5™ 
labeling kit and hybridized on the miRCURY™ LNA (locked nucleic acid) Array 
(v.10.0). Three independent hybridizations for each sample were performed on chips 
with each miRNA spotted in quadruplicate. Labeling efficiency was evaluated by 
analyzing the signals from control spike-in capture probes. LNA-modified capture 
probes corresponding to human, mouse, and rat mature sense miRNA sequences 
were spotted on slides. The resulting signal intensity values were normalized to per-
chip median values and then used to obtain geometric means and standard 
deviations for each miRNA. Triplicate arrays were performed under each treatment 
condition. 
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4. Results 
 
 
4.1. Role of the tyrosine-phosphorylated BCR-ABL 
SH3 domain 
 
The aim of the present study was to assess the potential interference of SH3 domain 
phosphorylation with the binding profile of BCR-ABL. In this regard we initially 
aspired to address both, the gain-of-function scenario as well as the loss-of-function 
scenario, upon Tyr134 phosphorylation.  
 
 
4.1.1. In vitro phosphorylation and GST pull-down 
 
First, the SH3 domain of BCR-ABL and the carboxy-terminal SH3 domain of GRB2 
were cloned into a bacterial expression vector, and following IPTG induction, the 
amino-terminal His-tag and Glutathion-S-Transferase (GST) tagged SH3 constructs 
were purified via Fast Protein Liquid Chromatography (FPLC) (Fig. 1A). In addition to 
the wild-type forms of the two SH3 domains, constructs were generated, where the 
corresponding tyrosine residues, Tyr134 of BCR-ABL and Tyr209 of GRB2, 
respectively, were replaced by a phenylalanine.  
In a next step we intended to in vitro phosphorylate the purified SH3 domains 
stoichiometrically with a recombinant and constitutively active ABL kinase domain 
(ABL-CD). The phosphorylated SH3 constructs were then supposed to be 
immobilized on glutathione-coupled sepharose, exploiting the GST tag of the SH3 
fusion proteins. Total cell lysates from K562 cells were then planned to be subjected 
to GST pull-down analyses, allowing the identification of specific interactors of the 
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phosphorylated and unphosphorylated BCR-ABL and GRB2 SH3 domains by mass-
spectrometry (Fig. 4.1). 
 
 Figure 4.1 Recombinant protein purification and in vitro phosphorylation. 
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To test the efficiency of SH3 in vitro phosphorylation, the purified SH3 domains were 
incubated with ABL-CD and either cold or radioactively labeled ATP. The presumably 
phosphorylated SH3 domains were subsequently separated from their amino-
terminal tags by the action of recombinant TEV protease. The TEV cleavage site 
usually consists of the amino acid sequence ENLYFQG, the cleavage occurring 
between the Q and the G residues. The tyrosine residue within this sequence was 
mutated beforehand to a phenylalanine, preventing its interference with the in vitro 
phosphorylation of the SH3 domain.  
Finally, detection of phosphorylated SH3 was accomplished by immunoblotting or 
autoradiography. In vitro phosphorylation with unlabeled ATP did not yield any SH3 
assignable signal on a Western Blot (data not shown). Radiolabeling on the other 
hand, proved to be more reliable, showing a clear difference in the signal intensity 
between phosphorylated and unphosphorylated SH3 constructs (Fig. 1B). 
Nevertheless, phosphorylation efficiency was significantly lower for the SH3 domain 
than for either the GST part of the protein or the positive control CRK-II, a known 
substrate of BCR-ABL (data not shown). 
To summarize, the stoichiometric phosphorylation of the SH3 domain as well as the 
detection of phosphorylated SH3 revealed to be rather problematic. The relatively low 
molecular weight of the BCR-ABL and GRB2 SH3 domains (6.6 and 7.4 kDa, 
respectively) and the probable inefficiency of SH3 domain phosphorylation by ABL-
CD were decisive in reasoning against this approach. 
 
 
4.1.2. Peptide pull-downs 
 
Because of the setbacks encountered in the GST pull-down approach, a different 
strategy had to be designed to analyze the relationship between SH3 domain 
phosphorylation and the BCR-ABL interaction profile. As a consequence we decided 
to merely concentrate on the gain-of-function situation where SH2 domain containing 
proteins are supposed to recognize the tyrosine-phosphorylated form of the BCR-
ABL SH3 domain.  
 
The interaction between SH2 domains and their respective phosphopeptide ligands 
can be described as an interaction occurring between short unstructured amino acids 
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and modular protein domains that are specialized on peptide binding. In search for 
BCR-ABL interactors that contain such SH2 modules and are recognizing 
phosphorylated Y134, the use of synthetic peptides as baits in affinity pull-down 
experiments appeared to be a straightforward method.  
 
Because of their bipartite binding surface, SH2 domains tend to bind 
phosphotyrosine residues depending on their sequence context. In a recent 
publication the sequence specificity of 76 human SH2 domains was assessed using 
an oriented peptide array library (OPAL). Based on the obtained data a web based 
prediction tool was established (http://lilab.uwo.ca/SMALI.htm), predicting which SH2 
domains potentially interact with a query phosphopeptide. For the Y134 
phosphopeptide of the BCR-ABL SH3 domain it predicted to be recognized by the 
carboxy-terminal SH2 domains of RASA1 and PLCG1, and the CRK SH2 domain. 
  
In order to verify those predicted interactions, and to see in general which other SH2 
domains might be recruited to the BCR-ABL SH3 domain, synthetic peptides, 12 
amino acids in length, were ordered from Eurogentec. The sequence of the peptides 
corresponded to the region of interest of the BCR-ABL SH3 domain and the GRB2 
carboxy-terminal SH3 domain, harboring Y134 and Y209, respectively (Fig. 4.2). The 
synthetic peptides were used in 'active' (i.e. phosphorylated) and 'control' (i.e. non-
phosphorylated) forms as baits in affinity pull-down experiments to reveal direct 
binders of the phosphorylated SH3 domains. In the „active‟ peptides a phosphate was 
covalently attached to the tyrosine‟s hydroxyl group, whereas in the „control‟ peptides 
the respective tyrosine residue was substituted by a phenylalanine.  
The peptides were subsequently coupled to agarose beads using the SulfoLink® 
Immobilization Kit for Peptides from Pierce Biotechnology.  All peptides contained a 
cysteine residue at position 12, allowing the formation of a thioether bond with the 
iodoacetyl-group of the agarose beads. 
Pull-down experiments were performed exposing the immobilized bait peptides to 
total cell extracts from K562 cells. Following LC-ESI-MS/MS analysis of the eluted 
protein complexes and subtraction of the proteins found in the respective control pull-
downs, a list of potentially specific interactors was obtained for the BCR-ABL and the 
GRB2 SH3 phosphopeptides. According to our model, such specific phosphopeptide 
interactors are expected to contain at least one phospho-tyrosyl binding domain. 
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Therefore, in a final step, domain analyses of the potential interactors was 
performed, yielding two SH2 harboring proteins in the case of the BCR-ABL 
phosphopeptide and three SH2 harboring proteins for the GRB2 phosphopeptide. 
 
Figure 4.2 Peptide pull-down. 
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For the BCR-ABL SH3 domain, 659 protein groups were identified in the 
phosphopeptide pull-down and 638 protein groups were found in the control pull-
down. In the case of the GRB2 carboxy-terminal SH3 domain the number of 
identified protein groups amounted to 712 for the phosphopeptide pull-down, and 641 
for the control pull-down.  
After subtraction of the corresponding control pull-downs, 44 and 77 protein groups 
were listed in the dataset of the BCR-ABL and GRB2 phosphopeptide pull-downs, 
respectively. Following domain analyses all proteins that were not containing a 
phospho-tyrosyl binding domain were excluded from that list, leaving us with those 
proteins whose interaction with the SH3 domains of BCR-ABL and GRB2 is likely to 
require a phosphotyrosine docking site. 
 
The phospholipase PLCG1 and the protein phosphatase PTPN11 (also called SHP2) 
were the only two proteins fulfilling those criteria for the BCR-ABL phosphopeptide. 
Both candidates are multidomain proteins that in addition to their catalytic domains 
contain two SH2 domains. Strikingly, both proteins were found to bind also to the 
Tyr209 phosphopeptide of GRB2, which was additionally recognized by the adaptor 
protein CRK-II.  
PLCG1 and SHP2 were the most frequent proteins in the Tyr134 phosphopeptide 
pull-down sample, the unspecific interactors not taken into account (Table 4.1). A 
similar situation was observed for the GRB2 phosphopeptide, where PLCG1 and 
CRK-II were among the most frequent of the specific interactors (Table 4.2) 
 
To confirm the interaction between the BCR-ABL and GRB2 phosphopeptides and 
PLCG1 and SHP2, 2% of the pull-down eluates were subsequently analyzed for the 
presence of PLCG1 and SHP2 on a Western Blot (Fig. 4.3).  Both proteins were 
detected in the phosphopeptide pull-down samples only, with no signal being spotted 
in the control samples. The detection of PLCG1 and SHP2 in the Tyr134 and Tyr209 
phosphopeptide eluates came not unexpectedly, given that, depending on the 
antibody, the immunoreactive detection of a certain protein is expected to be more 
sensitive than the mass spectrometry based approach. However, the renewed failure 
to detect PLCG1 and SHP2 in the control pull-downs, even by this, more sensitive, 
method, was corroborating the initial notion that both proteins bind to the SH3 
domains of BCR-ABL and GRB2 in the tyrosine phosphorylated state only. 
 4. RESULTS 
42 
 
 
 
 
 
Beyond the structural similarity between the two SH3 domains, Tyr134 of the BCR-
ABL SH3 domain and Tyr209 of the GRB2 carboxy-terminal SH3 domain are in 
addition located in a comparable sequence context. As mentioned earlier, the 
interaction between an SH2 domain and a phospho-tyrosine containing site is 
depending on the identity of the amino acids immediately C-terminal to the tyrosine 
residue. Therefore, we expected that SH2 domains binding to phosphorylated Tyr134 
of BCR-ABL are also recognizing, at least to some extent, the phosphorylated form of 
Tyr209 of GRB2. The fact that PLCG1 and SHP2 were indeed recruited by both 
phosphopeptides confirmed us in our intention to further evaluate their interaction 
with the BCR-ABL SH3 domain.  
 
 
To confirm the specific interaction between the tyrosine-phosphorylated BCR-ABL 
SH3 domain and PLCG1 and SHP2, additional peptide pull-downs were conducted, 
the experimental design remaining unchanged, with the exception of the GRB2 
peptides that were no longer included.  
Although peptide count and sequence coverage did not measure up to the numbers 
of the initial run, PLCG1 and SHP2 were nevertheless unambiguously shown to 
specifically bind the phosphorylated form of Tyr134 of the BCR-ABL SH3 domain 
(data not shown). The apparently decreased affinity of PLCG1 and SHP2 to the 
BCR-ABL phosphopeptide might be on account of the instability of the 
phosphopeptides after an extended period in solution. 
 
 
Figure 4.3 Immunoblot analysis of pull-down eluates. 
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Potein-
Name 
Peptide 
Count 
Sequence-
Coverage (%) 
CDD-Domains SMART-Domains 
PLCG1 31 22,64 PLCc, SH2, SH3, PH_PLC, C2_2 
PLCYc, PLCXc, C2, SH3, 
PH, SH2 
PTPN11 10 18,89 SH2, PTPc, PTPc PTPc, SH2 
CAP1 6 16,63 CARP, CAP CARP 
PHGDH 5 10,32 2-Hacid_dh_C, 2-Hacid_dh, SerA 
 
GLUD1 5 8,78 GLFV_dehydrog_N, GdhA 
 
GLUD2 5 8,78 GLFV_dehydrog_N, GdhA 
 
TKT 5 8,51 
Transketolase_C, Transket_pyr, 
TPP_TK, TktA  
SFPQ 5 7,92 RRM, RRM_1 RRM 
G6PD 5 8,07 G6PD_C, G6PD_N 
 
EEA1 5 3,61 COG4372, Smc, FYVE FYVE, ZnF_C2H2 
LACTB 3 8,04 Beta-lactamase 
 
GTPBP6 3 9,18 HflX, HflX 
 
HRMT1L2 3 9,62 COG4076 
 
FAM98A 3 7,92 
  
FKBP5 3 7,22 TPR, FKBP_C 
 
DLD 3 6,29 Pyr_redox_dim, Lpd, THI4 
 
DDX28 3 6,30 DEADc, HELICc HELICc, DEXDc 
XPNPEP3 3 6,11 PepP, AMP_N, Prolidase 
 
MRE11A 3 5,29 Metallophos, Mre11_DNA_bind 
 
TRIP4 3 4,65 Zf-C2HC5 
 
SOD1 2 18,18 Cu-Zn_Superoxide_Dismutase 
 
TCEB2 2 13,66 ElonginB UBQ 
SNRPB 2 12,08 Sm_B Sm 
GSTO1 2 9,96 
GST_N_Omega, GST_C_Omega, 
Gst  
UFD1L 2 8,79 UFD1 
 
SF3B4 2 5,90 RRM RRM 
KPNA6 2 5,22 IBB, ARM, SRP1 ARM 
LOC728340 2 5,06 
 
VWA 
LOC730394 2 5,06 
 
VWA 
GTF2H2 2 5,06 
vWA_transcription_factor_IIH_type, 
SSL1 
VWA 
LOC653866 2 5,06 
 
VWA 
DKFZP686
M0199 
2 5,00 
 
VWA 
SGPL1 2 4,58 Pyridoxal_deC 
 
KPNA1 2 4,65 IBB, ARM, SRP1 ARM 
PSMD5 2 4,37 
  
CBS 2 3,81 
COG3620, PALP, COG4109, CBS, 
CysK 
CBS 
GMPS 2 3,46 
GMP_synthase_C, GuaA, 
GATase1_GMP_Synthase  
ZNF689 2 3,20 COG5048, KRAB KRAB, ZnF_C2H2 
HYOU1 2 2,90 HSP70 
 
APLP2 2 2,62 KU, A4_EXTRA KU, A4_EXTRA 
SEC3L1 2 2,28 
  
LOC91664 2 1,77 
 
KRAB, ZnF_C2H2 
KTN1 2 1,69 Smc 
 
SMARCA4 2 1,34 
DEXHc, SNF2_N, HELICc, BRK, 
BROMO, HSA 
HSA, BROMO, HELICc, 
BRK, DEXDc 
Table 4.1 Specific interactors of the BCR-ABL Y134 phosphopeptide.  
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Protein-
Name 
Peptide 
Count 
Sequence-
Coverage (%) 
CDD-Domains SMART-Domains 
PLCG1 36 29,38 PLCc, SH2, SH3, PH_PLC, C2_2 
PLCYc, PLCXc, C2, SH3, 
PH, SH2 
DSP 8 3,45 Smc, SPEC, PLEC PLEC, SPEC 
RENT1 7 5,81 DEXDc, UvrD-helicase, COG1112 
 
CRK 6 36,27 SH2, SH3 SH3, SH2 
VSIG8 6 20,05 
 
IG, IGc2 
LRRC15 6 14,63 LRR_RI 
LRR_TYP, LRRNT, 
LRRCT 
JUP 6 11,54 VATPase_H, ARM ARM 
MCM5 6 9,67 MCM MCM 
MRE11A 5 7,94 Metallophos, Mre11_DNA_bind 
 
TBL2 5 13,65 
 
WD40 
TOE1 5 12,75 CAF1 
 
G6PD 5 9,54 G6PD_C, G6PD_N 
 
KRT39 4 14,66 Filament 
 
LOC728765 4 14,66 
  
COPS4 4 12,32 RPN5 PINT 
GOT1 4 11,38 Aminotran_1_2, TyrB 
 
ACADVL 4 7,79 CaiA, VLCAD 
 
DSG4 4 5,58 Cadherin_C, CA CA 
S100A3 3 33,66 S-100/ICaBP-like 
 
KRTAP13-2 3 28,57 PMG 
 
PARK7 3 17,46 GATase1_DJ-1 
 
PSMB5 3 14,07 proteasome_beta_type_5 
 
MRPL38 3 8,09 RKIP 
 
AHCY 3 6,71 AdoHcyase, SAM1 
 
PTPN11 3 6,24 SH2, PTPc, PTPc PTPc, SH2 
HBS1L 3 6,14 
EF1_alpha, eRF3_II_like, TEF1, 
HBS1_C  
SLC3A2 3 6,03 Aamy 
 
ZCCHC4 3 5,65 
 
ZnF_C2HC 
ATP6V1B2 3 5,48 
ATP-synt_ab_C, ATP-synt_ab_N, 
NtpB, V_A-ATPase_B  
PLOD3 3 4,34 P4Hc P4Hc 
ACO2 3 4,36 
AcnA_Mitochon_Swivel, AcnA, 
AcnA_Mitochondrial  
CAPN1 3 4,20 Calpain_III, EFh, CysPc EFh, CysPc, calpain_III 
NPEPPS 3 4,00 PepN, Peptidase_M1 
 
VDP 3 3,22 
Uso1_p115_C, Smc, 
Uso1_p115_head  
OGDHL 3 2,97 
Transket_pyr, SucA, 
TPP_E1_OGDC_like  
OGDH 3 2,93 
Transket_pyr, SucA, 
TPP_E1_OGDC_like  
COPB 3 2,83 COG5096, Adaptin_N 
 
SEC31L1 3 2,62 WD40 WD40 
KRTAP3-1 2 24,49 
  
KRTAP9-3 2 20,13 
  
KRTAP9-8 2 20,13 
  
CALML3 2 19,46 FRQ1, EFh EFh 
KRTAP9-5 2 18,93 
  
KRTAP9-2 2 18,39 
  
Table 4.2 Specific interactors of the GRB2 Y209 phosphopeptide.  
 4. RESULTS 
45 
 
SPRR1B 2 17,98 
  
SPRR1A 2 17,98 
  
KRTAP11-1 2 15,34 PMG 
 
KRTAP4-3 2 12,82 
  
LOC643287 2 12,71 
  
RAN 2 11,11 RAN, Ran RAN 
LGALS3 2 8,80 GLECT GLECT 
MAT2B 2 7,49 RfbD, FabG, RmlD_sub_bind 
 
PHB2 2 7,36 Band_7_prohibitin PHB 
LASP1 2 8,81 SH3, LIM, NEBU SH3, LIM, NEBU 
DNAJA1 2 6,55 
DnaJ_C, DnaJ, DnaJ, 
DnaJ_CXXCXGXG 
DnaJ 
ERAL1 2 6,18 Era, Era 
 
SERPINB5 2 5,60 maspin_like SERPIN 
VASP 2 5,53 Ena-Vasp WH1 
FKBP5 2 5,03 TPR, FKBP_C 
 
SMARCE1 2 4,87 HMGB-UBF_HMG-box HMG 
CANX 2 4,73 Calreticulin 
 
LOC728340 2 4,56 
 
VWA 
LOC730394 2 4,56 
 
VWA 
GTF2H2 2 4,56 
vWA_transcription_factor_IIH_type, 
SSL1 
VWA 
LOC653866 2 4,56 
 
VWA 
DKFZP686
M0199 
2 4,50 
 
VWA 
FDFT1 2 4,08 Trans_IPPS_HH 
 
ZCCHC8 2 3,82 zf-CCHC, PSP ZnF_C2HC, PSP 
FLJ21908 2 3,61 TPR TPR 
LOC652798 2 3,48 
  
LRRC40 2 3,32 COG4886, LRR_RI LRR_TYP 
COPG 2 3,32 SEC21 
 
PKP1 2 2,81 ARM ARM 
HNRPUL2 2 2,41 
 
SPRY, SAP 
IARS2 2 2,17 IleRS_core, zf-FPG_IleRS, IleS 
 
SMARCC1 2 1,90 SWIRM, MDN1, RSC8 CHROMO, SANT 
PFAS 2 1,87 
AIRS_C, GATase1_FGAR_AT, 
PurL_repeat2, PurL_repeat1, PurL  
 
 
4.1.3 Validation of the peptide pull-down approach 
 
The application of a phosphopeptide pull-down strategy for the identification of 
proteins docking to specific phospho-tyrosyl sites is a rather novel approach. It was 
hence our ambition to prove its validity. 
In the already mentioned study by Huang et al. the peptide ligand consensus 
sequence of 76 human SH2 domains was either established or redefined. Each SH2 
domain was analyzed for its sequence preference. More specifically, it was 
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established which amino acids a given SH2 domain favours in the P-2 to P+4 region 
that is flanking the phospho-tyrosyl site of the peptide ligand.  
We utilized these findings for the design of two phosphopeptides that based on the 
published consensus motifs are predicted to be bona fide targets for the SH2 
domains of PLCG1 and SHP2, and SRC (Table 4.3). Because of the overlapping 
sequence preferences of the PLCG1 and SHP2 SH2 domains, we managed to 
design a single phosphopeptide ligand that is presumably recognized by both 
proteins (Table 4.3). The second phosphopeptide was designed to be bound 
primarily by SRC.  
 
 
 
Established SH2 Binding Motifs 
 
 
P-2 P-1 P+1 P+2 P+3 P+4 
PLCG1_N ? ? ? ? ? ? 
PLCG1_C x x L ≥ V ≥ I > T L > M P ≥ I ≥ L x 
PTPN11_N L > H > V x V ≥ L > I x L ≥ M L ≥ M 
PTPN11_C x M V > I > T > L ≥ S ≥ E D > M I > M ≥ V > A M 
SRC P > H I > P E > D > V > I L > I > E I > L > V D 
       Designed Phosphopeptides 
 
P-2 P-1 P+1 P+2 P+3 P+4 
PLCG1/SHP2 ligand L M V M L M 
SRC ligand P I E E I D 
 
 
We performed two additional peptide pull-downs, both times using the Tyr134 
phosphopeptide and control peptide, as well as the two newly designed „validation 
peptides‟. The pull-down protocols were identical to the initial pull-down; the only 
exception was that for one of the two pull-downs we used 0.1 M formic acid instead 
of 1% SDS in the elution step. 
We subsequently tested the eluates for the presence of PLCG1 and SHP2 by 
Immunoblotting (Fig. 4.4). We detected two bands that corresponded to PLCG1, only 
the upper band being specific to the phosphopeptide pull-down. SHP2 was neither 
detected in the phosphopeptide nor in the control pull-down. Again, the prolonged 
storage in solution is likely to be responsible for the decreased phosphopeptide 
affinity for PLCG1 and SHP2. 
Table 4.3 Peptide design.  
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As far as the „validation peptides‟ are concerned, the PLCG1/SHP2 motif peptide was 
bound by the PLCG1 and SHP2, the SHP2 signal being considerably stronger. The 
SRC motif peptide was only bound by PLCG1, indicating that the PLCG1 SH2 
domains are less sequence specific. It is however noteworthy that the amino-terminal 
SH2 domain of PLCG1 was shown to be required for PDGF-induced enzyme 
activation, while the carboxy-terminal SH2 domain was not 289. As the sequence 
specificity of the amino-terminal SH2 domain has so far not been described, we could 
only consider the sequence preferences of the carboxy-terminal SH2 domain when 
designing the PLCG1/SHP2 motif peptide. 
Based on the SHP2 data it is however safe to assume that the peptide pull-down 
approach is valid for the identification of phospho-tyrosine specific SH2 domain 
harbouring interactors. 
 
 
  
Figure 4.4 Validation pull-downs.  
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4.1.4 GST pull-down 
 
Next, we sought to verify the interaction between PLCG1 and SHP2 and the SH3 
domain of BCR-ABL in a less artificial system. We therefore decided to fall back on 
the initial GST pull-down approach, although in a slightly modified version (Fig. 4.5) 
Instead of being subjected to an in vitro phosphorylation step prior to the actual pull-
down procedure, the FPLC purified His-tag and GST tagged BCR-ABL SH3 
constructs were immediately immobilized on glutathione-coupled sepharose. As 
described earlier, the immobilized SH3 constructs were subsequently incubated with 
a freshly prepared K562 cell extract. In this context, the cell lysate is not only serving 
as a pool of potential protein interactors, but is also supplying the kinases that are 
presumably involved in SH3 domain phosphorylation (e.g. BCR-ABL or SFKs).  
Compared to the in vitro phosphorylation approach, this approach is more likely to 
reflect the actual percentage of phosphorylated BCR-ABL SH3 domains normally 
found in K562 cells. However, a decrease in the efficiency of SH3 domain 
phosphorylation goes hand in hand with a reduced likelihood of identifying specific 
alterations in the SH3 domain binding pattern.  
Considering the relative abundance of PLCG1 and SHP2 in the phosphopeptide pull-
downs, we were nevertheless optimistic to detect different levels of PLCG1 and 
SHP2 in the respective GST pull-downs. 
 
We included five different SH3 constructs in the pull-down experiment (Fig. 4.6A). In 
the wild-type construct (WT) the sequence of the BCR-ABL SH3 domain was 
unchanged. In the Y134F construct Tyr134 was replaced by a phenylalanine. 
Construct number three was a triple mutant where all three tyrosine residues that are 
located within the BCR-ABL SH3 domain were replaced by a phenylalanine 
(Y89/112/134F). In the remaining two constructs, the tryptophan residue involved in 
the polyproline type II helix recognition of the SH3 domain, W118, was mutated to an 
alanine, Tyr134 either being present or being replaced by a phenylalanine (W118A 
and W118A Y134F). 
The substitution of the functionally important tryptophan residue was carried out to 
increase the probability of Tyr134 phosphorylation by the endogenous kinases 
present in the K562 lysate. It is conceivable that the interaction of the SH3 domain 
with conventional ligands is interfering with Tyr134 phosphorylation as the kinases 
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might be prevented from gaining access to the phosphorylation site. Thus, we hoped 
to undermine such a steric effect by interfering with the classical binding properties of 
the SH3 domain.  
Figure 4.5 GST pull-down assay.  
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Figure 4.6 Constructs used in GST pull-down and Co-IP assays.  
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Western Blot analysis of the pull-down eluates showed that PLCG1 interaction with 
the BCR-ABL SH3 domain is significantly reduced in the Y134F mutant compared to 
the wild-type form, and is even undetectable in the triple mutant (Fig. 4.7). PLCG1 
seems therefore to be recruited to the phosphorylated form of the BCR-ABL SH3 
domain via its SH2 domains, given that the interaction requires the presence of 
tyrosine residues. Moreover, the specificity pockets of the PLCG1 SH2 domains 
evidently prefer the Tyr134 phosphopeptide over the other two tyrosine containing 
sites of the BCR-ABL SH3 domain. It has to be noted that while Tyr89 has been 
reported to be phosphorylated, there exist no such reports involving Tyr112. 
PLCG1 could not be detected in the pull-down samples of the W118A and W118A 
Y134F constructs. While this might be expected for the double mutant it came as a 
surprise for the W118A construct. At least according to our model, Tyr134 
phosphorylation and hence PLCG1 recruitment should be facilitated in the W118A 
mutant. A possible explanation for the absence of such an effect could be improper 
domain folding upon introduction of the W118A point mutation. 
Unfortunately, we could not confirm the interaction of SHP2 with the phosphorylated 
SH3 domain of BCR-ABL by this approach. 
 
 
 
Figure 4.7 Immunoblot analysis of GST pull-down eluates.  
 4. RESULTS 
52 
 
4.1.5 Co-immunoprecipitation 
 
Finally, we sought to prove the interaction occurring between our candidates and the 
BCR-ABL SH3 domain in the context of the full-length BCR-ABL protein. Co-
immunoprecipitation (Co-IP) experiments were designed to address the role of 
Tyr134 phosphorylation in the recruitment of PLCG1 and SHP2.  
Different full-length BCR-ABL constructs were generated and used in the Co-IP (Fig. 
4.6B), similar to the SH3 constructs used in the GST pull-downs. The constructs, 
listed in Fig. 4.6B, were denoted as BCR-ABL WT, BCR-ABL Y134F, BCR-ABL 
W118A R171L and BCR-ABL W118A Y134F R171L. The W118A and R171L point 
mutations were introduced for the same reason for which W118A was included in the 
GST pull-down constructs. Both residues, W118A of the BCR-ABL SH3 domain, and 
R171 of the BCR-ABL SH2 domain, are thought to be involved in the cooperative 
binding of either SH3 or SH2 domain ligands. Replacement of these residues by non 
functional amino acids was therefore expected to abrogate conventional SH3 
mediated interactions, thus making Y134 more accessible for phosphorylation.  
The MYC-tagged BCR-ABL constructs were transiently transfected in HEKnull cells. 
Then, immunoprecipitation of BCR-ABL and immunoblot analysis were conducted to 
detect endogenous PLCG1 and SHP2 in the compound of the BCR-ABL protein 
complexes (Fig. 4.8).  
The association of PLCG1 and SHP2 with BCR-ABL was significantly reduced in the 
BCR-ABL Y134F and BCR-ABL W118A R171L Y134F mutants compared to the 
BCR-ABL wild-type form. For BCR-ABL W118A R171L the results are rather 
inconclusive; in Fig. 4.8A PLCG1 interaction with BCR-ABL W118A R171L was ~1.5 
fold increased compared to BCR-ABL WT, whereas in Fig. 4.8B the levels of 
detected PLCG1 were reduced to ~40% of the wild-type situation. Analogously, the 
levels of co-immunoprecipitated SHP2 were comparable for BCR-ABL WT and BCR-
ABL W118A R171L in Fig. 4.8A, whereas in Fig. 4.8B SHP2 could only be detected 
in the BCR-ABL WT Co-IP.  
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We assume that only a small percentage of BCR-ABL molecules is actually 
phosphorylated on Tyr134. This being said, it is not unexpected that the band 
intensities of PLCG1 and SHP2 in the Co-IP experiments are generally quite low.  
Furthermore, it is possible that the lower levels of PLCG1 and SHP2 in the Y134F 
Co-IPs are mere background signals that derive from unspecific binding. Although 
this issue might be solved by applying a stricter washing procedure, at the same time 
the immunoreactive detection of both candidates would probably be rendered 
impossible. 
 
Overall, these data provide convincing evidence that the interaction of PLCG1 and 
SHP2 with BCR-ABL is largely dependent on the presence of Tyr134, indicating a 
binding interface involving the SH2 domains of PLCG1 and SHP2 and a 
phosphorylated Tyr134 residue. Even so, because of the numerous tyrosine residues 
of BCR-ABL it cannot be excluded that other sites are contributing to the interaction, 
albeit to only a minor extent.  
 
 
Figure 4.8 Co-immunoprecipitation assay.  
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4.2. BCR-ABL mediated microRNA deregulation 
 
 
4.2.1 Reduced miR-21 levels 
 
MiRNA-21 levels in K562 cells were observed to be ~3.5 fold reduced after Dasatinib 
treatment. To validate miR-21 expression as determined by the microarray-based 
gene expression profiling and to acquire more quantitative information, miR–qRT-
PCR was performed on RNA isolated from K562 cells treated for four hours with 
either 100nM Dasatinib or 1µM Nilotinib. As shown in Fig. 4.9, miR-qRT-PCR 
confirmed the BCR-ABL dependent expression of miR-21 for both Dasatinib and 
Nilotinib treated cells. The reduced miR-21 levels result in higher Ct values compared 
to the untreated samples, thus decreasing the measured ΔCt. As reference served 
RNU43 (SNORD43), a small nucleolar RNA (snoRNA) involved in pre-rRNA 
processing and modification. The Ct values of RNU43 were higher than for miR-21 
and were supposed to stay unaffected by the drug treatment. As a consequence, the 
higher the ΔCt (RNU43-miR-21) values are, the more miR-21 molecules are present 
in the sample. 
To better visualize the altered miR-21 levels, the relative fold changes of miR-21 
expression, untreated versus treated K562 cells, determined by miR-qRT-PCR, were 
assessed using the ΔΔCt method. As shown in Fig. 4.9, both Dasatinib and Nilotinib 
treatment reduced miR-21expression to similar extents. A 40% reduction of miR-21 
levels was observed after Dasatinib treatment and a 50% reduction after Nilotinib 
treatment. 
 
These results confirm the initial observations that miR-21 expression is indeed 
downregulated upon inhibition of the BCR-ABL kinase activity by small molecule 
chemical inhibitors like Dasatinib or Nilotinib. Formulated in a different way, miR-21 
expression is upregulated in CML cells in a BCR-ABL dependent manner. 
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To study the biological significance of elevated miR-21 expression, we applied a 
gain-of-function, as well as a loss-of-function approach in K562 cells. We 
manipulated miR-21 levels by transfecting miR-21 mimics in K562 cells to 
supplement miR-21 activity. Analogously, K562 cells were transfected with anti-miR-
21, which bind to endogenous miR-21 and thereby antagonize its activity.  To allow a 
distinction between inhibitory activity and background effects, we included a non-
targeting anti-miR as a negative control in the experiment. K562 cells were harvested 
72 hours after treatment and mir-21 levels were quantified by miR-qRT-PCR. As 
expected, miR-21 mimic treatment caused a marked increase of miR-21 levels and 
while the negative control showed no effect, application of anti-miR-21 led to a 0.4 
fold reduction of miR-21 levels (Fig. 4.10). 
 
Yet, when we tested the differently treated K562 cells in a preliminary experiment for 
the differential expression of proposed miR-21 target genes (Bcl-2, STAT3, p21 and 
p-AKT downstream of PTEN) no effect could be observed (data not shown). Cell 
viability and apoptotic rate were also unaffected (data not shown). 
Although this data has yet to be verified and microRNA target genes are likely to vary 
from cell type to cell type, it is possible that the redundant activation of different 
growth and survival pathways in CML cells is concealing potential miR-21 mediated 
alterations. 
Figure 4.9 MiR-21 downregulation in Dasatinib and Nilotinib treated K562 
cells (miR-qRT-PCR). 
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4.2.2. MicroRNA microarray 
 
With the aim of characterizing the miRNA expression profile of untreated K562 cells 
and Dasatinib or Nilotinib treated K562 cells, a miRNA-based microarray chip assay 
(miCHIP), conducted by Exiqon, was used to screen for differentially expressed 
miRNAs.  
To search for BCR-ABL dependent miRNA expression, K562 cells were treated with 
either Dasatinib (100nm for 4h) or Nilotinib (1µM for 4h) to inhibit BCR-ABL tyrosine 
kinase activity. Each treatment was performed in triplicate. In a next step, total RNA 
was isolated using the mirVana miRNA Isolation Kit from Ambion. The quality of the 
RNA samples was assessed using the Agilent 2100 Bioanalyzer, allowing the 
standardization of RNA integrity interpretation. The RNA Integrity Number (RIN) 
measures RNA quality and grades it on a quantitative scale of 1 (poor) to 10 (high). 
 
After submission of all nine RNA samples, three for each treatment, miRNA 
expression profiling was performed by Exiqon, applying the most recent version of 
the miRCURY LNA™ microRNA Array.  According to Exiqon the array covers all 
human, mouse and rat microRNA sequences annotated in miRBase 10.0, including 
94 miRNAs of the viruses related to these three species. Additionally the array 
Figure 4.10 MiR-21 antagomirs and mimics in K562 cells (miR-qRT-PCR).  
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contains 43 capture probes for the detection of miRPlus microRNAs, which are 
human miRNAs unique to Exiqon. In total, 758 human microRNAs can be detected 
using the array. 
 
Among the miRNAs analyzed, 31 were found to be differentially expressed in the 
different samples comparing drug treated groups and untreated samples (Fig. 4.11, 
Fig. 4.12). The Nilotinib sample group showed to be significantly more different to the 
untreated group than Dasatinib treated samples. 
 
Strikingly, for the majority of the downregulated miRNAs only the microRNA star form 
(miRNA*) was detected to be affected by BCR-ABL inhibition. In theory, cleavage of 
pre-miRNA hairpins produces a duplex composed of two small RNAs. One of the two 
strands initially produced in a 1:1 ratio by transcription usually accumulates to a 
higher level than its partner. Because of the preferred stability of miRNA species and 
the concomitant turnover of miRNA* species the mature miRNA/miRNA* ratio is 
asymmetric at steady state, sometimes at a discrepancy of >10 000:1 290, 291. The 
mature miRNA strand serves as guide strand in the miRISC complex whereas the 
poorly expressed partner strand, termed miRNA*, was thought to be functionally 
irrelevant. However, recently miRNA* species were implicated as players in the 
miRNA regulatory network 292-294. It was shown that some miRNA* sequences are 
inhabiting AGO complexes and exert a regulatory function. Also, many miRNA* 
sequences are present at physiological relevant levels, and most miRNA* seed 
regions and their complementary 3‟UTRs are substantially constrained during 
evolution.  
We are assuming that drug treatment for four hours is not sufficient to reduce the 
levels of the mature miRNA strands in a significant and hence detectable way. 
MiRNA* species on the other hand are less stable and have a higher turnover rate, 
resulting in a marked drop of the corresponding miRNA* strand levels, even after 
drug treatment for only four hours. Thus, downregulation of miRNA expression is 
initially causing a reduction in the number of miRNA* strands, and is only later 
manifesting on the mature miRNA level. MiRNA hairpins whose physiological levels 
are high enough to be detected by miCHIP are likely to produce two distinct 
regulatory RNAs, thereby broadening their regulatory network and their spectra of 
potential target genes.   
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20 human microRNAs were shown to be downregulated in K562 cells following drug 
treatment. Importantly, downregulation of miR-21 expression was confirmed by the 
miCHIP assay. MiR-21* levels were reduced ~0.5 and ~0.6 fold in the Dasatinib and 
Nilotinib treated cells, respectively. Based on the assumption that a reduction in 
miRNA* levels is a harbinger of the ensuing decrease of the mature miRNA levels, 
miR-21 expression was found to be BCR-ABL dependent. Strikingly, miR-590-5p, the 
only miRNA containing the same 7nt seed region and therefore the same target 
genes as miR-21, was also shown to be downregulated. 
Consistent with the findings of Venturini et al., expression of miRNAs within the 
polycistronic miR-17-92 cluster (encoding miR-17, miR-18a, miR-19a, miR-20a, miR-
19b-1, and miR-92-1) and one of its paralog clusters, miR-106a-363 (miR-106a, miR-
18b, miR-20b, miR-19b-2, miR-92a-2, and miR-363), is specifically downregulated by 
both Dasatinib and Nilotinib treatment.  
 
Among the 758 human miRNAs analyzed, 11 were found to be upregulated by both 
Dasatinib and Nilotinib treatment. Interestingly, the levels of miR-155, a presumably 
oncogenic miRNA, were also increased in the drug treated compared to the 
untreated cells. 
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 Figure 4.11 Differentially regulated miRNAs (log2 median ratios). 
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Figure 4.12 Differentially regulated miRNAs (fold change). 
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We then sought to elucidate the role of miRNA deregulation in BCR-ABL signalling. 
We compared the list of the predicted target genes of the deregulated miRNAs we 
identified by miCHIP with the list of genes whose expression profile was shown to be 
altered following Dasatinib treatment in the initial microarray experiment (i.e. the one 
that led to the discovery of miR-21 downregulation in Dasatinib treated K562 cells) 
(Table 4.3). 
Genes whose expression levels were increased in Dasatinib treated cells were 
matched against the predicted target genes of those miRNAs whose expression 
levels were reduced by the drug treatment. Contrariwise, genes whose expression 
was repressed following Dasatinib treatment were matched against the targets of the 
upregulated miRNAs. 
Especially for the downregulated miRNAs we detected a redundancy concerning 
their target genes. This was not unexpected, given that almost half of them belonged 
to the miR-17-92 family and considering that polycistronic miRNAs often share 
identical seeds.  
Table 4.4 and 4.5 list all the genes that are potentially targeted by more than one 
miRNA. Nonetheless, it remains to be seen which genes are really regulated by the 
corresponding miRNAs and to which extent their differential expression in Dasatinib 
treated cells can be attributed to the relief or onset of miRNA mediated post 
transcriptional gene silencing (PTGS). 
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MicroRNA Seed (5'-3') Predicted Targets (TargetScan) 
hsa-miR-17 AAAGUGC 
AHNAK, C1orf63, C9orf5, CCNG2, CENPO, CNN1, CYBRD1, EPB41, ERBB3, FAM46C, 
FRMD4A, FZD4, HBP1, KIAA0831, MARCH8, MGEA5, MLL3, PGM2L1, PIK3R1, RRAGD, 
SH3BP5, SLC16A9, SLC40A1, TAL1, TP53INP1, WNK1, ZBTB4 
hsa-miR-18a AAGGUGC RABGAP1, ZBTB4 
hsa-miR-18a* CUGCCCU CITED2, DLC1, EFNA1, FZD4, ZBTB4 
hsa-miR-19a GUGCAAA 
ABHD5, C10orf26, CEP350, DAAM1, DLC1, ELL2, ERBB3, FAM46C, HBP1, ID2, 
KIAA0831, KRAS, MBD4, PGM2L1, PIK3R3, PLCL2, PNRC1, RABGAP1, RCOR3, 
TP53INP1, WNK1, ZBTB4, ZFPM2 
hsa-miR-19a* GUUUUGC CITED2, DLC1, FRMD4A, HOXC13, PIK3R1  
hsa-miR-20a AAAGUGC 
AHNAK, C1orf63, C9orf5, CCNG2, CENPO, CNN1, CYBRD1, EPB41, ERBB3, FAM46C, 
FRMD4A, FZD4, HBP1, KIAA0831, MARCH8, MGEA5, MLL3, PGM2L1, PIK3R1, RRAGD, 
SH3BP5, SLC16A9, SLC40A1, TAL1, TP53INP1, WNK1, ZBTB4 
hsa-miR-20a* CUGCAUU KIAA0831, MYST4, PAQR8, ZNF318 
hsa-miR-19b-1 GUGCAAA 
ABHD5, C10orf26, CEP350, DAAM1, DLC1, ELL2, ERBB3, FAM46C, HBP1, ID2, 
KIAA0831, KRAS, MBD4, PGM2L1, PIK3R3, PLCL2, PNRC1, RABGAP1, RCOR3, 
TP53INP1, WNK1, ZBTB4, ZFPM2 
hsa-miR-19b-1* GUUUUGC CITED2, DLC1, FRMD4A, HOXC13, PIK3R1  
hsa-miR-92a-1 AUUGCAC 
ATP2B4, CDKN1C, CEP350, ING2, KIAA0831, MITF, PFKFB4, PIK3R3, SERTAD3, 
SYNJ1, ZFPM2 
hsa-miR-92a-1* GGUUGGG 
 
hsa-miR-106a AAAGUGC 
AHNAK, C1orf63, C9orf5, CCNG2, CENPO, CNN1, CYBRD1, EPB41, ERBB3, FAM46C, 
FRMD4A, FZD4, HBP1, KIAA0831, MARCH8, MGEA5, MLL3, PGM2L1, PIK3R1, RRAGD, 
SH3BP5, SLC16A9, SLC40A1, TAL1, TP53INP1, WNK1, ZBTB4 
hsa-miR-20b AAAGUGC 
AHNAK, C1orf63, C9orf5, CCNG2, CENPO, CNN1, CYBRD1, EPB41, ERBB3, FAM46C, 
FRMD4A, FZD4, HBP1, KIAA0831, MARCH8, MGEA5, MLL3, PGM2L1, PIK3R1, RRAGD, 
SH3BP5, SLC16A9, SLC40A1, TAL1, TP53INP1, WNK1, ZBTB4 
hsa-let-7a GAGGUAG 
ATP2B4, CBX2, DLC1, EPB41, FGD6, FZD4, GLRX, HIC2, KLHDC8B, LGR4, PGM2L1, 
SLC16A9, TRIB1 
miR-21 AGCUUAU CCDC34, PIK3R1, ZFP36L2 
miR-21* AACACCA PIK3R3, RNF43 
hsa-miR-26b UCAAGUA 
CDKN1C, CEP350, FAM46C, MLL3, PGM2L1, PIK3R3, SLC25A37, THRAP3, TP53INP1, 
WNK1 
hsa-miR-30b GUAAACA 
AHNAK, BCL6, C10orf26, CBX2, CEP350, CSNK1A1, ELL2, EPB41, ERMAP, FAM46C, 
FAM73B, FGD6, FRMD4A, GLCCI1, HIC2, KRAS, MARCH8, MLL3, PGM2L1, SLC36A1, 
STIM2, TP53INP1 
hsa-miR-126 CGUACCG 
 
hsa-miR-146b-3p GCCCUGU KLHDC8B, PFKFB4, TFAP2B 
hsa-miR-154 AGGUUAU 
 
hsa-miR-154* AUCAUAC STIM2 
hsa-miR-181a ACAUUCA 
AHNAK, BAG4, BMF, CEP350, EPB41, FAM46C, FAM73B, GLCCI1, HIC2, KRAS, MLL3, 
PIK3R3, PLCL2, RABGAP1, RNF43, SLC25A37, STIM2, WNK1, ZBTB4, ZNF292 
hsa-miR-181a-2* CCACUGA KRAS, SYNJ1, TAL1 
hsa-miR-223 GUCAGUU C10orf26, ELL2, FAM46C, FRMD4A, MLL3, SETBP1, ZNF395 
hsa-miR-223* GUGUAUU CAV2, CEP350, DLC1, TFAP2B 
hsa-miR-379 GGUAGAC 
 
hsa-miR-379* AUGUAAC FRMD4A, HIC2, TFAP2B, ZNF292 
hsa-miR-493 GAAGGUC FAM102B, PIK3R1 
hsa-miR-493* UGUACAU 
 ATP2B4, CDKN1C, CITED2, CSNK1A1, FRMD4A, FZD4, HEMGN, HIC2, KIAA0831, 
PIK3R1, RXRA, WNK1 
hsa-miR-590-5p AGCUUAU CCDC34, PIK3R1, ZFP36L2 
 
Table 4.3 MiRNAs and target genes inversely regulated by drug treatment  
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Gene Name Full Name 
Fold 
Change 
Prediction 
Frequency 
FRMD4A FERM domain containing 4A 1,83 9 
KIAA0831 KIAA0831 1,69 9 
PGM2L1 phosphoglucomutase 2-like 1 1,80 9 
FAM46C family with sequence similarity 46, member C 1,65 8 
TP53INP1 tumor protein p53 inducible nuclear protein 1 1,67 8 
WNK1 WNK lysine deficient protein kinase 1 1,46 8 
FZD4 frizzled homolog 4 (Drosophila) 1,89 7 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) 1,66 7 
ZBTB4 zinc finger and BTB domain containing 4 1,49 7 
DLC1 deleted in liver cancer 1 1,81 6 
EPB41 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) 1,71 6 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 1,69 6 
HBP1 HMG-box transcription factor 1 1,45 6 
MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 1,51 6 
AHNAK AHNAK nucleoprotein (desmoyokin) 1,56 5 
CEP350 centrosomal protein 350kDa 1,65 5 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) 3,13 5 
MARCH8 membrane-associated ring finger (C3HC4) 8 1,68 5 
SLC16A9 solute carrier family 16 (monocarboxylic acid transporters), member 9 1,90 5 
TAL1 T-cell acute lymphocytic leukemia 1 1,56 4 
C1orf63 chromosome 1 open reading frame 63 1,76 4 
C9orf5 chromosome 9 open reading frame 5 1,61 4 
CCNG2 cyclin G2 2,45 4 
CITED2 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 
2 
2,67 4 
CNN1 calponin 1, basic, smooth muscle 1,63 4 
CYBRD1 cytochrome b reductase 1 1,83 4 
HIC2 hypermethylated in cancer 2 2,34 4 
MGEA5 meningioma expressed antigen 5 (hyaluronidase) 1,93 4 
RRAGD RAS-related GTP binding D 1,55 4 
SH3BP5 SH3-domain binding protein 5 (BTK-associated) 1,58 4 
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 2,33 4 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 1,46 3 
C10orf26 chromosome 10 open reading frame 26 1,49 3 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 3,66 3 
ELL2 elongation factor, RNA polymerase II, 2 1,57 3 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 1,72 3 
RABGAP1 RAB GTPase activating protein 1 1,66 3 
ZFPM2 zinc finger protein, multitype 2 1,67 3 
ABHD5 abhydrolase domain containing 5 1,55 2 
CBX2 chromobox homolog 2 (Pc class homolog, Drosophila) 1,66 2 
CSNK1A1 casein kinase 1, alpha 1 1,57 2 
DAAM1 dishevelled associated activator of morphogenesis 1 1,48 2 
FGD6 FYVE, RhoGEF and PH domain containing 6 2,09 2 
HOXC13 homeobox C13 2,25 2 
Table 4.4 Target genes of down-regulated miRNAs. Number of miRNAs targeting a certain gene 
(prediction frequency), fold change of target genes following Dasatinib treatment (fold change). 
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ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 2,38 2 
KLHDC8B kelch domain containing 8B 1,61 2 
MBD4 methyl-CpG binding domain protein 4 1,54 2 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 1,99 2 
PLCL2 phospholipase C-like 2 1,69 2 
PNRC1 proline-rich nuclear receptor coactivator 1 1,94 2 
RCOR3 REST corepressor 3 1,60 2 
STIM2 stromal interaction molecule 2 1,53 2 
TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 beta) 1,68 2 
 
 
 
 
Gene Name Full Name 
Fold 
Change 
Prediction 
Frequency 
ETV1 ets variant gene 1 -3,45 3 
CHSY1 carbohydrate (chondroitin) synthase 1 -1,70 2 
ENC1 ectodermal-neural cortex (with BTB-like domain) -2,15 2 
EPAS1 endothelial PAS domain protein 1 -1,98 2 
FAM60A family with sequence similarity 60, member A -1,99 2 
HCCS holocytochrome c synthase (cytochrome c heme-lyase) -1,68 2 
IGF1 insulin-like growth factor 1 (somatomedin C) -2,85 2 
KSR1 kinase suppressor of ras 1 -1,98 2 
PTP4A1 protein tyrosine phosphatase type IVA, member 1 -1,48 2 
RAN RAN, member RAS oncogene family -2,03 2 
SOCS1 suppressor of cytokine signaling 1 -7,20 2 
SPRED2 sprouty-related, EVH1 domain containing 2 -1,69 2 
ZC3H12C zinc finger CCCH-type containing 12C -2,00 2 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5 Target genes of up-regulated miRNAs. Number of miRNAs targeting a certain gene 
(prediction frequency), fold change of target genes following Dasatinib treatment (fold change). 
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5. Discussion 
 
 
5.1. Identification of novel interactors of BCR-ABL 
 
Translocation of c-ABL located on chromosome 9 to the breakpoint-cluster region 
(BCR) on chromosome 22 generates the fusion oncogene BCR-ABL.  It produces the 
chimeric, constitutively active, tyrosine kinase p210, whose presence is sufficient for 
malignant transformation of hematopoietic cells in culture 295, 296 and causes a CML-
like MPD in mice 6, 297. 
BCR-ABL exerts its oncogenic function by acting upstream of several important 
cellular signalling pathways. It contains multiple distinct sites and protein domains, 
which constitute the link to those pathways. In this study we were addressing the role 
the BCR-ABL SH3 domain plays in BCR-ABL signalling.  
Our interest in the SH3 domain originated from a recent report that demonstrated that 
BCR-ABL dependent tyrosine-phosphorylation of the GRB2 carboxy-terminal SH3 
domain prevents it from interacting with the SH3 ligand SOS 279.  Based on the 
extensive structural and sequence homologies shared by both SH3 domains we were 
wondering if phosphorylation of the BCR-ABL SH3 domain is affecting its binding 
pattern in a likewise manner.  
Under normal circumstances SH3 domains are specialized in the recognition of 
peptides displaying a polyproline type II helix conformation. We speculated that 
phosphorylation of Tyr134 of the BCR-ABL SH3 domain interferes with this type of 
interactions, at the same time generating a docking site for the recruitment of SH2 
domain harbouring proteins. In order to validate this hypothesis we applied a peptide 
pull-down strategy, the peptide sequences corresponding to the region of interest of 
the BCR-ABL SH3 domain and the GRB2 carboxy-terminal SH3 domain.  
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The SH2 domain containing proteins PLCG1 and SHP2 (PTPN11) were found to 
bind specifically to the Tyr134 (BCR-ABL) and Tyr209 (GRB2) phosphopeptides, but 
not to the unphosphorylated control peptides. We subsequently confirmed the 
specific interaction of PLCG1 and SHP2 with the tyrosine-phosphorylated BCR-ABL 
SH3 domain by applying a co-immunoprecipitation approach. PLCG1 and SHP2 
association with p210 was significantly reduced in the Y134F BCR-ABL mutants 
compared to the wild-type constructs, underscoring the importance of phosphorylated 
Y134 in this context.   
Finally, in GST-pull-downs, using GST-SH3 fusion proteins as bait, we observed a 
dramatic decrease of PLCG1 association with the BCR-ABL SH3 domain after the 
introduction of the Y134F mutation. 
Both proteins foster mitogenic signalling and have been implicated in proliferation 
and tumorigenesis 298, 299. We find it therefore tempting to speculate that PLCG1 and 
SHP2 are participating in BCR-ABL mediated transformation of hematopoietic cells 
and leukemogenesis.  
 
 
5.1.1. PLCG1 
 
In the phospholipase C-γ subfamily (PLCG1 and PLCG2 in mammals), the X and Y 
catalytic lipase domains are separated by a SH region containing two SH2 domains, 
an SH3 domain and a split PH domain (Fig. 5.1).  PLCG1 is a multidomain protein 
containing two SH2 domains and one SH3 domain between the catalytic lipase 
domains.  
 
 
 
 
 
The SH2 domains of PLCG1 have been implicated in the association between 
PLCG1 and activated receptor tyrosine kinases. Following recruitment to 
Figure 5.1 Domain structure of PLCG1. 
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autophosphorylated receptor tyrosine kinases (e.g. PDGFR) PLCG1 becomes 
phosphorylated and hence activated 300-302. The lipase activity of PLCG1 is then 
causing the generation of the two intracellular second messengers diacylglycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3) by cleavage of phosphatidylinositol-4,5-
bisphosphate, which in turn promote the activation of protein kinase C (PKC) and the 
release of Ca2+ form intracellular store 303, 304.  
The individual roles of the two SH2 domains of PLCG1 were investigated by 
functional inactivation of each domain and expression of the mutant proteins in a 
PLCG1-deficient fibroblast cell line 289. While the amino-terminal SH2 domain was 
required for PDGF-induced enzyme activation, the carboxy-terminal SH2 domain was 
not. In addition, it has been proposed that the SH2 domains are involved in PLCG1 
autoinhibition, functioning as an intramolecular „„cap‟‟ to occlude the active site in the 
absence of activating events 305. 
It is the SH3 domain rather than the catalytic domain of PLCG1 that has been 
reported to be essential for cellular proliferation and growth factor induced 
mitogenesis. The SH3 domain interacts with SOS, which leads to the activation of 
RAS and subsequently of the ERK-MAPK pathway 306. Additionally, the SH3 domain 
serves as a GEF (guanine nucleotide exchange factor) for Dynamin and PIKE, 
thereby potentiating ERK and PI3K activity, respectively 307, 308. On the other hand, 
negative regulation of PLCG1 is mainly mediated by the interaction of the PLCG1 
SH3 domain with CBL and the interaction of GRB2 with tyrosine phosphorylated 
PLCG1 309, 310. 
 
Homozygous disruption of the PLCG1 gene was shown to cause an embryonic lethal 
phenotype owing to growth attenuation 311.  Furthermore, PLCG1 was shown to 
participate in tumorigenesis. The expression level of PLCG1 was found to be 
elevated in cancer tissues compared to normal tissues 312, 313. Interestingly, 
overexpression of the PLCG1 SH2-SH2-SH3 domain in rat 3Y1 cells was reported to 
be sufficient to induce cellular transformation and to cause tumor mass generation 
when transplanted into nude mice 314. 
 
In a recent publication by Plattner et al. a link between the endogenous c-ABL 
tyrosine kinase and PLCG1 signalling was described 315.  According to the authors 
PLCG1 is acting upstream of c-ABL in PDGF induced chemotaxis and is required for 
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the PDGFR mediated activation of c-ABL. It was proposed that phosphatidylinositol-
4,5-bisphosphate (PIP2) is inhibiting c-ABL and that hydrolysis of PIIP2 by activated 
PLCG1 is releasing this restraint. They showed that c-ABL and PLCG1 form a 
complex in vivo, probably involving SH2-phosphotyrosine binding. A negative 
feedback loop was established where activated c-ABL negatively regulates PLCG1 
lipase activity through inhibitory tyrosine-phosphorylation. As a consequence PIP2 
levels are again increasing and interfering with c-ABL activity. 
 
Based on these facts it is conceivable that the SH2 domain mediated interaction of 
PLCG1 with the SH3 domain of Y134 phosphorylated BCR-ABL is adding a further 
boost to mitogenic signalling in K562 cells. Similar to the recruitment of PLCG1 to 
autophosphorylated RTKs, it appears plausible that in K562 cells, the PLCG1 SH2 
domains additionally recognize tyrosine phosphorylated BCR-ABL. Whether this 
interaction resembles the c-ABL – PLCG1 interaction, involving PLCG1 inhibition and 
PIP2 increase remains to be seen. However, regardless of the lipase activity, 
proliferation and survival pathways are anyway mainly activated via the PLCG1 SH3 
domain, leading to the activation of the mitogenic kinases ERK and PI3K. Moreover, 
considering the constitutive active nature of the BCR-ABL tyrosine kinase, negative 
regulation by PIP2 as observed for c-ABL can be neglected. 
 
 
5.1.2. SHP2 
 
The Src homology-2 (SH2) domain containing phosphatases (Shps) are a small, 
highly conserved subfamily of protein-tyrosine phosphatases. There exist two 
vertebrate Shps – SHP1 and SHP2. They have two tandemly arranged amino-
terminal SH2 domains (N-SH2 and C-SH2), a classic protein-tyrosine phosphatase 
(PTP) domain that displays absolute specificity for hydrolyzing phosphotyrosine, and 
a carboxy-terminal tail (C-tail) (Fig. 5.2). 
 
 
Figure 5.2 Domain structure of SHP2. 
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In the basal state the PTP domain is maintained in an inactive conformation by an 
intramolecular interaction involving the catalytic cleft of the PTP domain and the 
“back-side-loop” (the side opposing the phosphotyrosine binding surface) of the N-
SH2 domain 50, 316. This culminates in mutual allosteric inhibition, with the N-SH2 
domain suppressing PTP activity and the PTP domain contorting the phospho-tyrosyl 
binding pocket of the N-SH2 domain on the opposite surface of the N-SH2-PTP 
binding interface. The phospho-tyrosyl binding pocket of the C-SH2 domain is 
unperturbed and it was postulated that it is surveying the cell for appropriate 
phosphopeptides 50.  C-SH2 domain mediated binding of bisphosphorylated ligands 
is thought to increase the local phosphotyrosine concentration, thereby alleviating N-
SH2 inhibition by the PTP domain and enabling phosphatase activation 50. 
Alternatively, presence of high-affinity ligands for the N-SH2 domain or intramolecular 
interaction of the SH2 domains with the tyrosine phosphorylated C-tail was proposed 
to have the same effect.  
 
Protein-tyrosine phosphatases (PTPs) are conventionally thought to qualify as prime 
suspects for tumor suppressors by opposing protein-tyrosine kinase (PTKs) activities 
and attenuating pro-growth signalling. Surprisingly, only few phosphatase genes 
have been unequivocally identified as tumor suppressors. Be that as it may, SHP2 
(encoded by PTPN11) was found to be a bona fide proto-oncogene. Somatic gain-of-
function mutations in PTPN11 occur in juvenile myelomonocytic leukemia (JMML) 
and, more rarely, in adult and solid tumors 317-319. Germ line mutations of PTPN11 on 
the other hand cause Noonan syndrome and the Noonan-like LEOPARD syndrome 
320, 321. In both cases the mutation clusters occur in the N-SH2 and PTP domains, 
where they affect residues that are participating in basal inhibition and are heavily 
buried in the closed form.  The integrity of the autoinhibitory cleft structure is 
corrupted, causing constitutive phosphatase activity and retained N-SH2 domain 
capacity to bind tyrosine phosphorylated proteins 50. 
As a result SHP2 is constitutively activated, resulting in the continuing activation of 
the downstream RAS/ERK-MAPK pathway. 
 
Enhanced RAS/ERK pathway activation is probably the key feature of mutant SHP2 
evoked pathogenesis. In most RTK signalling pathways, SHP2 is required for 
enhanced and sustained activation of the ERK MAPK pathway 322, 323. Cells that are 
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lacking functional SHP2 usually exhibit defective RAS activation, placing SHP2 
upstream of RAS 324, 325. 
There exist different models of SHP2 mediated positive RAS/ERK signalling. One 
possibility is SHP2 induced dephosphorylation of RASGAP binding sites on RTKs, 
thereby interfering with RASGAP mediated suppression of RAS 326, 327. However, this 
model cannot explain the mechanism of SHP2 action in pathways where SHP2 is 
recruited to phosphorylated adaptor proteins rather than to RTKs. It is thought that 
the interaction between scaffolding adaptors and SHP2 is crucial to target SHP2 into 
the vicinity of its substrates. In an alternative model, this might allow the direct or 
indirect dephosphorylation of SFK inhibitory tyrosines, considering that expression of 
a GAB1-SHP2 fusion protein results in enhanced SRC activity and that SRC 
inhibitors prevent the fusion protein from activating ERK 328. 
Recent studies of oncogenic SHP2 mutants raise the possibility that the transcription 
factor ICSBP (IRF8) may be a key target that indirectly controls RAS pathway 
activation by regulating NF1 levels 329. SHP2 was shown to catalyze ICSBP 
dephosphorylation, rendering it unable to promote NF1 gene transcription, resulting 
in decreased NF1 levels and hyperactivation of the RAS/ERK pathway in myeloid 
progenitor cells 329. Support for this model comes from the observation that ICSBP−/− 
mice develop an MPD similar to that seen in mice expressing leukemogenic SHP2 
mutants 65. 
Ultimatively, SHP2 might contribute to RAS/ERK activation by dephosphorylation of 
SPROUTY proteins, proteins that in their tyrosyl-phosphorylated form have been 
implicated in local sequestration of RAS 330. 
  
SHP2 is highly expressed in hematopoietic cells and plays a critical role in 
hematopoietic cell development and function 331-333. SHP2 is also known to form a 
stable protein complex with p210 and to be heavily phosphorylated within this 
complex 334-336. At least in part this interaction occurs through the BCR-ABL 
autophosphorylation site Y177, which was previously shown to be recognized by 
GRB2. As described in the introduction, GRB2 is subsequently recruiting GAB2, 
which in turn is binding PI3K and SHP2.  
Growth factor-independent colony formation evoked by BCR-ABL is attenuated in 
GAB2-/- BM cells. Consistent with these findings, GAB2 is a crucial determinant of the 
 5. DISCUSSION 
71 
 
severity of BCR-ABL evoked leukemia, the PI3K and SHP2 binding sites being 
required for myeloid and lymphoid transformation 51.  
More importantly, SHP2 itself was found to be required for BCR-ABL mediated 
hematopoietic cell transformation 337. A knock-out of PTPN11 in hematopoietic cells 
compromised the leukemic potential of BCR-ABL due to proteasome mediated 
degradation of BCR-ABL and decreased oncogenic signalling 337. SHP2 was shown 
to positively regulate the stability of BCR-ABL through the interaction with heat shock 
protein 90 (HSP90). The role of SHP2 in the stability of p210 is independent of its 
catalytic activity. Overexpression of catalytically-inactive SHP2 did not lead to p210 
degradation but it nevertheless attenuated cell survival and enhanced serum 
starvation-induced apoptosis 337. SHP2 therefore appears to also function in BCR-
ABL downstream oncogenic signalling. 
 
Mirroring the proposed interaction between PLCG1 and BCR-ABL, the SH2 domain 
mediated recruitment of SHP2 to the Y134 phosphorylated SH3 domain of BCR-ABL 
might confer a further enhancement to leukemic signalling.  
However, SHP2 was already found to be associated with BCR-ABL via GAB2 at 
phosphorylated Y177 in the BCR region of the fusion protein. Also, bone marrow 
myeloid progenitors form GAB2 defective mice were shown to be resistant to 
transformation by BCR-ABL 51, an effect that at least in part was attributed to 
decreased SHP2 association. These findings are rather arguing against a possible 
redundancy of Y177 (BCR) and Y134 (ABL) in SHP2 recruitment and signalling. 
On the other hand, our co-immunoprecipitation experiments clearly demonstrate that 
mutation of Y134 to phenylalanine is dramatically reducing the percentage of BCR-
ABL associated SHP2, underlining the weightiness of this interaction site.  
 
 
5.1.3. Conclusions 
 
Although we assume that only a small portion of the p210 molecules is actually 
phosphorylated in the SH3 domain and that in addition PLCG1 and SHP2 must 
compete for these few SH2 domain binding sites, the oligomeric nature of BCR-ABL 
might compensate for this. It is conceivable that BCR-ABL oligomerization allows the 
simultaneous and spatially collocated engagement of the “complexed” SH3 domains 
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with canonical ligands via its PxxP binding site and with PLCG1 and SHP2 via 
phosphorylated Y134.  
In conclusion, to our knowledge this is the first study showing a phosphotyrosine 
dependent interaction between a SH2 domain and a SH3 domain.  Our findings 
emphasize the complexity of the molecular basis of CML and suggest that even well 
characterized protein modules can have concealed features that go beyond their 
conventional modus operandi.  
 
To further characterize the SH3 domain mediated interaction of BCR-ABL with 
PLCG1 and SHP2 the functional relevance of this interaction will have to be 
addressed. For a start, transient transfection of HEK cells with either BCR-ABL wild-
type constructs or BCR-ABL Y134F constructs and subsequent functional studies 
could shed some light on the underlying mechanisms. It is conceivable that for 
example differences in the transforming potential, the proliferation rate, the apoptotic 
rate, etc., will be observed. Also, one might look for changes at the level of the 
effector proteins in the signalling pathways downstream of PLCG1 and SHP2 (e.g. 
ERK phosphorylation, PKC and PI3K activity...).  
Moreover, it will be interesting to see whether and how the phosphorylation patterns 
of SHP2, PLCG1 and BCR-ABL differ in BCR-ABL WT and BCR-ABL Y134F 
transfected cells and if overexpression of phosphatase dead SHP2, harboring the 
C459S mutation, affects BCR-ABL tyrosine-phosphorylation. 
Finally, more information about PLCG1 and SHP2 in CML could be gained by 
characterizing the respective interactomes by performing tandem affinity purifications 
(TAPs). 
 
 
5.2. MicroRNA deregulation in BCR-ABL suppressed 
cells 
 
MiR-21 is a known oncogenic miRNA that was shown to be overexpressed in a 
variety of human malignancies 231. Known miR-21 target genes include tumor 
suppressor genes like PTEN, TPM1, PDCD4, or SERPINB5 264, 266-269, 274. 
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Accordingly, elevated miR-21 levels are usually connected to enhanced cell survival 
and metastasis.  
We have previously found miR-21 expression to be ~3.5 fold decreased following 
Dasatinib treatment of K562 cells on a protein microarray, raising the question of 
whether miRNAs in general and miR-21 in particular are involved in the manifestation 
of CML.  
We now confirmed by miR-21 specific miR-qRT-PCR that inhibition of the BCR-ABL 
tyrosine kinase in K562 cells by either Dasatinib or Nilotinib treatment is indeed 
ensued by miR-21 downregulation. 
To address the physiological role of miRNAs in BCR-ABL mediated leukemogenesis 
on a more extended level we looked for Dasatinib and Nilotinib induced alterations in 
the expression levels of all human miRNAs in K562 cells performing a miRNA-based 
microarray chip assay.  
We found 31 miRNAs to be differentially expressed depending on whether the cells 
were subjected to drug treatment or not. Among these candidates are several 
miRNAs that have already been shown to possess either tumor-suppressive or 
oncogenic potential. 
Most prominently, downregulation of miR-21 after drug treatment was confirmed by 
the miRNA microarray data. After four hour drug treatment, the amount of miR-21* 
strands was reduced to ~50%.  
In general most downregulated miRNAs of our dataset were only detected at the star 
strand (miRNA*) level. Considering that miRNA* strands are generally present in 
much lower numbers and have a higher turnover rate than their complementary 
counterparts, the mature miRNA strands, it is only logical that reduced transcriptional 
activity will initially have a more dramatic effect on the miRNA* population.  
Although drug treatment for four hours is apparently often not sufficient to reduce 
mature miRNA levels to a detectable degree, harvesting at a later time point might 
distort the results. K562 cells rely on the presence of catalytically active BCR-ABL, 
which is why the longer the drug mediated interference with the tyrosine kinase 
activity takes, the faster the apoptotic rate of the affected cells becomes. As 
apoptosis is accompanied by the activation of various cell death associated 
pathways, it would no longer be permissible to draw a direct connection between 
miRNA deregulation and BCR-ABL inhibition. 
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In accordance with earlier reports that implicated transcriptional activation of the miR-
17-92 polycistronic cluster in oncogenesis we found members and paralogs of this 
miRNA family to be negatively regulated by both Dasatinib and Nilotinib treatment. 
Venturini et al. have shown that overexpression of a variant of miR-17-92 in K562 
cells induces increased cell proliferation and antagonizes anti-c-MYC RNAi mediated 
proliferation arrest 249. The authors postulated the existence of a BCR-ABL – c-MYC 
– miR-17-92 signalling pathway where miR-17-92 downstream of c-MYC positively 
regulates cell proliferation and survival. 
 
We additionally identified several miRNAs that were upregulated in Dasatinib and 
Nilotinib treated cells. With the exception of miR-155 these miRNAs have so far no 
assigned role in tumorigenesis. As for miR-155, it is of notice that it was expressed at 
significantly higher levels in drug treated cells compared to the untreated samples. 
Based on previous reports, suggesting that miR-155 is acting as an oncogene, one 
would rather expect its upregulation in CML.  
 
As a first step in the analysis of the relationship between candidate miRNA 
expression and BCR-ABL in CML, we used the web based miRNA target gene 
prediction tool at „www.targetscan.org‟ to look for overlapping hits in the microarray 
dataset of genes that were found to be deregulated by Dasatinib. We found several 
potential miRNA target genes whose expression levels are inversely correlated with 
the levels of their targeting miRNA following drug treatment. However further studies 
will be required to verify some of this target genes and to elucidate their role in 
leukemogenesis. 
In summary, the identification of these 31 differentially expressed miRNAs could 
represent a further step toward the identification of gene regulatory networks involved 
in CML pathogenesis. 
 
In order to validate some of the potential miRNA target genes, qRT-PCR 
experiments, targeting the respective mRNAs, will have to be performed, comparing 
the mRNA expression levels in dependence of BCR-ABL activity or in the presence 
of respective miRNA antagomirs or mimics. To prove the translational repression by 
a specific miRNA, it will ultimately be necessary to generate 3´-UTR-reporter 
constructs, where the 3´UTR of the suspected target gene is cloned downstream of a 
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luciferase reporter gene. Transient transfection of the reporter construct and the 
corresponding miRNA mimic in cells with a low endogenous expression for this 
specific miRNA, followed by subsequent monitoring of the reporter activity allows the 
confirmation of a miRNA – target gene relationship. 
Alternatively, if antibodies for the gene product of a certain target gene are available, 
one could determine by immunoblotting if treatment with a specific miRNA mimic or 
antagomir is showing an effect at the protein level. 
Additionally, treatment of K562 cells with specific miRNA mimics or inhibitors, 
combined with microarray-based gene expression profiling, would enable us to 
further characterize the role of a certain miRNA in CML. 
Finally, deconvolution of the large and complex dataset could be accomplished by 
the bioinformatic analysis of miRNA – target genes networks, thereby entitling us to 
discern relevant connections and pathways that might be vital to BCR-ABL mediated 
leukemogenesis. 
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